Sprimeo

1 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX I 

 

SUMMARY OF PRODUCT CHARACTERISTICS 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



2 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 150 mg film-coated tablets 

 

 

2. QUALITATIVE AND QUANTITATIVE COMPOSITION 

 

Each film-coated tablet contains 150 mg aliskiren (as hemifumarate). 

 

For a full list of excipients, see section 6.1. 

 

 

3. PHARMACEUTICAL FORM 

 

Film-coated tablet 

 

Light-pink, biconvex, round tablet, imprinted “IL” on one side and “NVR” on the other side. 

 

 

4. CLINICAL PARTICULARS 

 

4.1 Therapeutic indications 

 

Treatment of essential hypertension. 

 

4.2 Posology and method of administration 

 

The recommended dose of Sprimeo is 150 mg once daily. In patients whose blood pressure is not 

adequately controlled, the dose may be increased to 300 mg once daily. 

 

The antihypertensive effect is substantially present within two weeks (85-90%) after initiating therapy 

with 150 mg once daily. 

 

Sprimeo may be used alone or in combination with other antihypertensive agents with the exception 

of use in combination with angiotensin converting enzyme inhibitors (ACEI) or angiotensin II 

receptor blockers (ARB) in patients with diabetes mellitus or renal impairment (glomerular filtration 

rate (GFR) < 60 ml/min/1.73 m
2
) (see sections 4.3, 4.4 and 5.1). 

 

Sprimeo should be taken with a light meal once a day, preferably at the same time each day. 

Grapefruit juice should not be taken together with Sprimeo. 

 

Renal impairment 

No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see 

sections 4.4 and 5.2). Sprimeo is not recommended in patients with severe renal impairment (GFR 

< 30 ml/min/1.73 m
2
). Concomitant use of Sprimeo with ARBs or ACEIs is contraindicated in 

patients with renal impairment (GFR < 60 ml/min/1.73 m
2
) (see section 4.3). 

 

Hepatic impairment 

No adjustment of the initial dose is required for patients with mild to severe hepatic impairment (see 

section 5.2). 

 

Elderly patients (over 65 years) 

The recommended starting dose of aliskiren in elderly patients is 150 mg. No clinically meaningful 

additional blood pressure reduction is observed by increasing the dose to 300 mg in the majority of 

elderly patients. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



3 

Paediatric patients (below 18 years) 

Sprimeo is not recommended for use in children and adolescents below age 18 due to a lack of data on 

safety and efficacy (see section 5.2). 

 

4.3 Contraindications 

 

Hypersensitivity to the active substance or to any of the excipients. 

 

History of angioedema with aliskiren. 

 

Hereditary or idiopathic angioedema. 

 

Second and third trimesters of pregnancy (see section 4.6). 

 

The concomitant use of aliskiren with ciclosporin and itraconazole, two highly potent P-gp inhibitors, 

and other potent P-gp inhibitors (e.g. quinidine), is contraindicated (see section 4.5). 

 

The concomitant use of aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes 

mellitus or renal impairment (GFR < 60 ml/min/1.73 m
2
) (see sections 4.2, 4.4, 4.5 and 5.1). 

 

4.4 Special warnings and precautions for use 

 

Aliskiren should be used with caution in patients with serious congestive heart failure (New York 

Heart Association [NYHA] functional class III-IV). 

 

In the event of severe and persistent diarrhoea, Sprimeo therapy should be stopped. 

 

Dual blockade of the renin-angiotensin-aldosterone system (RAAS) 

Hypotension, syncope, stroke, hyperkalaemia, and changes in renal function (including acute renal 

failure) have been reported in susceptible individuals, especially if combining medicinal products that 

affect this system (see section 5.1). Dual blockade of the renin-angiotensin-aldosterone system by 

combining aliskiren with an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II 

receptor blocker (ARB) is therefore not recommended. 

 

The use of aliskiren in combination with ARBs or ACEIs is contraindicated in patients with diabetes 

mellitus or renal impairment (GFR < 60 ml/min/1.73 m
2
) (see section 4.3). 

 

Angioedema 

As with other agents acting on the renin-angiotensin system, angioedema or symptoms suggestive of 

angioedema (swelling of the face, lips, throat and/or tongue) have been reported in patients treated 

with aliskiren. 

 

A number of these patients had a history of angioedema or symptoms suggestive of angioedema, 

which in some cases followed use of other medicines that can cause angioedema, including RAAS 

blockers (angiotensin converting enzyme inhibitors or angiotensin receptor blockers) (see section 4.8). 

 

Patients with a history of angioedema may be at increased risk of experiencing angioedema during 

treatment with aliskiren (see sections 4.3 and 4.8). Caution should therefore be exercised when 

prescribing aliskiren to patients with a history of angioedema, and such patients should be closely 

monitored during treatment (see section 4.8) especially at the beginning of the treatment. 

 

If angioedema occurs, Sprimeo should be promptly discontinued and appropriate therapy and 

monitoring provided until complete and sustained resolution of signs and symptoms has occurred. 

Where there is involvement of the tongue, glottis or larynx adrenaline should be administered. In 

addition, measures necessary to maintain patent airways should be provided. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



4 

Sodium and/or volume depleted patients 

In patients with marked volume- and/or salt-depletion (e.g. those receiving high doses of diuretics) 

symptomatic hypotension could occur after initiation of treatment with Sprimeo. This condition 

should be corrected prior to administration of Sprimeo, or the treatment should start under close 

medical supervision. 

 

Renal impairment 

In clinical studies Sprimeo has not been investigated in hypertensive patients with severe renal 

impairment (serum creatinine ≥ 150 μmol/l or 1.70 mg/dl in women and ≥ 177 μmol/l or 2.00 mg/dl in 

men and/or estimated GFR < 30 ml/min/1.73 m
2
), history of dialysis, nephrotic syndrome or 

renovascular hypertension. Sprimeo is not recommended in patients with severe renal impairment 

(GFR < 30 ml/min/1.73 m
2
). 

 

As for other agents acting on the renin-angiotensin system, caution should be exercised when aliskiren 

is given in the presence of conditions pre-disposing to kidney dysfunction such as hypovolaemia (eg. 

due to blood loss, severe prolonged diarrhoea, prolonged vomiting, etc.), heart disease, liver disease, 

diabetes mellitus or kidney disease. The concomitant use of aliskiren and ACEIs or ARBs is 

contraindicated in patients with renal impairment (GFR < 60 ml/min/1.73 m
2
). Acute renal failure, 

reversible upon discontinuation of treatment, has been reported in at-risk patients receiving aliskiren 

in post-marketing experience. In the event that any signs of renal failure occur, aliskiren should be 

promptly discontinued. 

 

Increases in serum potassium have been observed with aliskiren in post-marketing experience and 

these may be exacerbated by concomitant use of other agents acting on the RAAS or by non-steroidal 

anti-inflammatory drugs (NSAIDs). Consistent with standard medical practice, periodic determination 

of renal function including serum electrolytes is advised if co-administration is considered necessary. 

 

Renal artery stenosis 

No controlled clinical data are available on the use of Sprimeo in patients with unilateral or bilateral 

renal artery stenosis, or stenosis to a solitary kidney. However, as with other agents acting on the 

renin-angiotensin system, there is an increased risk of renal insufficiency, including acute renal 

failure, when patients with renal artery stenosis are treated with aliskiren. Therefore, caution should 

be exercised in these patients. If renal failure occurs, treatment should be discontinued. 

 

Moderate P-gp inhibitors 

Co-administration of aliskiren 300 mg with ketoconazole 200 mg or verapamil 240 mg resulted in a 

76% or 97% increase in aliskiren AUC, respectively. Therefore caution should be exercised when 

aliskiren is administered with moderate P-gp inhibitors such as ketoconazole or verapamil (see section 

4.5). 

 

4.5 Interaction with other medicinal products and other forms of interaction 

 

The combination of aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes 

mellitus or renal impairment (GFR < 60 ml/min/1.73 m
2
) and is not recommended in other patients 

(see sections 4.3, 4.4 and 5.1). 

 

Compounds that have been investigated in clinical pharmacokinetic studies include acenocoumarol, 

atenolol, celecoxib, pioglitazone, allopurinol, isosorbide-5-mononitrate and hydrochlorothiazide. No 

interactions have been identified. 

 

Co-administration of aliskiren with either metformin (↓28%), amlodipine (↑29%) or cimetidine 

(↑19%) resulted in between 20% and 30% change in Cmax or AUC of Sprimeo. When administered 

with atorvastatin, steady-state Sprimeo AUC and Cmax increased by 50%. Co-administration of 

Sprimeo had no significant impact on atorvastatin, metformin or amlodipine pharmacokinetics. As a 

result no dose adjustment for Sprimeo or these co-administered medicinal products is necessary. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



5 

Digoxin and verapamil bioavailability may be slightly decreased by Sprimeo. 

 

In experimental animals, it has been shown that P-gp is a major determinant of Sprimeo 

bioavailability. Inducers of P-gp (St. John’s wort, rifampicin) might therefore decrease the 

bioavailability of Sprimeo. 

 

CYP450 interactions 

Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A). 

Aliskiren does not induce CYP3A4. Therefore aliskiren is not expected to affect the systemic 

exposure of substances that inhibit, induce or are metabolised by these enzymes. Aliskiren is 

metabolised minimally by the cytochrome P450 enzymes. Hence, interactions due to inhibition or 

induction of CYP450 isoenzymes are not expected. However, CYP3A4 inhibitors often also affect P-

gp. Increased aliskiren exposure during co-administration of CYP3A4 inhibitors that also inhibit P-gp 

can therefore be expected (see P-glycoprotein interactions below). 

 

P-glycoprotein interactions 

MDR1/Mdr1a/1b (P-gp) was found to be the major efflux system involved in intestinal absorption and 

biliary excretion of aliskiren in preclinical studies. Rifampicin, which is an inducer of P-gp, reduced 

aliskiren bioavailability by approximately 50% in a clinical study. Other inducers of P-gp (St. John’s 

wort) might decrease the bioavailability of Sprimeo. Although this has not been investigated for 

aliskiren, it is known that P-gp also controls tissue uptake of a variety of substrates and P-gp 

inhibitors can increase the tissue-to-plasma concentration ratios. Therefore, P-gp inhibitors may 

increase tissue levels more than plasma levels. The potential for drug interactions at the P-gp site will 

likely depend on the degree of inhibition of this transporter. 

 

P-gp potent inhibitors 

A single dose drug interaction study in healthy subjects has shown that ciclosporin (200 and 600 mg) 

increases Cmax of aliskiren 75 mg approximately 2.5-fold and AUC approximately 5-fold. The increase 

may be higher with higher aliskiren doses. In healthy subjects, itraconazole (100 mg) increases AUC 

and Cmax of aliskiren (150 mg) by 6.5-fold and 5.8-fold, respectively. Therefore, concomitant use of 

aliskiren and P-gp potent inhibitors is contraindicated (see section 4.3). 

 

Moderate P-gp inhibitors 

Co-administration of ketoconazole (200 mg) or verapamil (240 mg) with aliskiren (300 mg) resulted 

in a 76% or 97% increase in aliskiren AUC, respectively. The change in plasma levels of aliskiren in 

the presence of ketoconazole or verapamil is expected to be within the range that would be achieved if 

the dose of aliskiren were doubled; aliskiren doses of up to 600 mg, or twice the highest 

recommended therapeutic dose, have been found to be well tolerated in controlled clinical trials. 

Preclinical studies indicate that aliskiren and ketoconazole co-administration enhances aliskiren 

gastrointestinal absorption and decreases biliary excretion. Therefore, caution should be exercised 

when aliskiren is administered with ketoconazole, verapamil or other moderate P-gp inhibitors 

(clarithromycin, telithromycin, erythromycin, amiodarone). 

 

P-gp substrates or weak inhibitors 

No relevant interactions with atenolol, digoxin, amlodipine or cimetidine have been observed. When 

administered with atorvastatin (80 mg), steady-state aliskiren (300 mg) AUC and Cmax increased by 

50%. 

 

Organic anion transporting polypeptide (OATP) inhibitors 

Preclinical studies indicate that aliskiren might be a substrate of organic anion transporting 

polypeptides. Therefore, the potential exists for interactions between OATP inhibitors and aliskiren 

when administered concomitantly (see interaction with Grapefruit juice). 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



6 

Furosemide 

When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced 

by 28% and 49% respectively. It is therefore recommended that the effects be monitored when 

initiating and adjusting furosemide therapy to avoid possible underutilisation in clinical situations of 

volume overload. 

 

Non-steroidal anti-inflammatory drugs (NSAIDs) 

As with other agents acting on the renin-angiotensin system, NSAIDs may reduce the anti-

hypertensive effect of aliskiren. In some patients with compromised renal function (dehydrated 

patients or elderly patients) aliskiren given concomitantly with NSAIDs may result in further 

deterioration of renal function, including possible acute renal failure, which is usually reversible. 

Therefore the combination of aliskiren with an NSAID requires caution, especially in elderly patients. 

 

Medicinal products affecting serum potassium levels 

Concomitant use of other agents affecting the RAAS, of NSAIDs or of agents that increase serum 

potassium levels (e.g. potassium-sparing diuretics, potassium supplements, salt substitutes containing 

potassium, heparin) may lead to increases in serum potassium. If co-medication with an agent 

affecting the level of serum potassium is considered necessary, caution is advisable. The combination 

of aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes mellitus or renal 

impairment (GFR < 60 ml/min/1.73 m
2
) and is not recommended in other patients (see sections 4.3, 

4.4 and 5.1). 

 

Grapefruit juice 

Administration of grapefruit juice with aliskiren resulted in a decrease in AUC and Cmax of aliskiren. 

Co-administration with aliskiren 150 mg resulted in a 61% decrease in aliskiren AUC and co-

administration with aliskiren 300 mg resulted in a 38% decrease in aliskiren AUC. This decrease is 

likely due to an inhibition of organic anion transporting polypeptide-mediated uptake of aliskiren by 

grapefruit juice in the gastrointestinal tract. Therefore, because of the risk of therapeutic failure, 

grapefruit juice should not be taken together with Sprimeo. 

 

Warfarin 

The effects of Sprimeo on warfarin pharmacokinetics have not been evaluated. 

 

Food intake 

Meals with a high fat content have been shown to reduce the absorption of Sprimeo substantially. 

 

4.6 Fertility, pregnancy and lactation 

 

Pregnancy 

There are no data on the use of aliskiren in pregnant women. Sprimeo was not teratogenic in rats or 

rabbits (see section 5.3). Other substances that act directly on the RAAS have been associated with 

serious foetal malformations and neonatal death. As for any medicine that acts directly on the RAAS, 

Sprimeo should not be used during the first trimester of pregnancy or in women planning to become 

pregnant and is contraindicated during the second and third trimesters (see section 4.3). Healthcare 

professionals prescribing any agents acting on the RAAS should counsel women of childbearing 

potential about the potential risk of these agents during pregnancy. If pregnancy is detected during 

therapy, Sprimeo should be discontinued accordingly. 

 

Breast-feeding 

It is not known whether aliskiren is excreted in human milk. Sprimeo was secreted in the milk of 

lactating rats. Its use is therefore not recommended in women who are breast-feeding. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



7 

4.7 Effects on ability to drive and use machines 

 

No studies on the effects on the ability to drive and use machines have been performed. However, 

when driving vehicles or operating machinery it must be borne in mind that dizziness or weariness 

may occasionally occur when taking any antihypertensive therapy. Sprimeo has negligible influence 

on the ability to drive and use machines. 

 

4.8 Undesirable effects 

 

Sprimeo has been evaluated for safety in more than 7,800 patients, including over 2,300 treated for 

over 6 months, and more than 1,200 for over 1 year. The incidence of adverse reactions showed no 

association with gender, age, body mass index, race or ethnicity. Treatment with Sprimeo resulted in 

an overall incidence of adverse reactions similar to placebo up to 300 mg. Adverse reactions have 

generally been mild and transient in nature and have only infrequently required discontinuation of 

therapy. The most common adverse drug reaction is diarrhoea. 

 

The adverse drug reactions (Table 1) are ranked under heading of frequency, the most frequent first, 

using the following convention: very common (≥1/10); common (≥1/100, <1/10); uncommon 

(≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000); very rare (<1/10,000) and not known (cannot be 

estimated from the available data). Within each frequency grouping, undesirable effects are presented 

in order of decreasing seriousness. 

 

Table 1 

 

Nervous system disorders 

 Common: Dizziness 

Vascular disorders 

 Uncommon: Hypotension 

Gastrointestinal disorders 

 Common: Diarrhoea 

Immune system disorders 

 Rare: Hypersensitivity reactions 

Skin and subcutaneous tissue disorders 

 Uncommon: Rash, severe cutaneous adverse reactions (SCARs) including toxic 

epidermal necrolysis (TEN) and oral mucosal reactions 

 Rare: Angioedema 

Musculoskeletal and connective tissue disorders 

 Common: Arthralgia 

Renal and urinary disorders 

 Uncommon: Acute renal failure, renal impairment 

General disorders and administration site conditions 

 Uncommon: Oedema peripheral 

Investigations 

 Common: Hyperkalaemia 

 Rare: Haemoglobin decreased, haematocrit decreased 

 Rare: Blood creatinine increased 

 

Angioedema and hypersensitivity reactions have occurred during treatment with aliskiren. In 

controlled clinical trials, angioedema and hypersensitivity reactions occurred rarely during treatment 

with aliskiren with rates comparable to treatment with placebo or comparators. 

 

Cases of angioedema or symptoms suggestive of angioedema (swelling of the face, lips, throat and/or 

tongue) have also been reported in post-marketing experience. A number of these patients had a 

history of angioedema or symptoms suggestive of angioedema which in some cases was associated 

with the administration of other medicines known to cause angioedema, including RAAS blockers 

(ACE inhibitors or ARBs). 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



8 

 

Hypersensitivity reactions have also been reported in post-marketing experience. 

 

In the event of any signs suggesting a hypersensitivity reaction/angioedema (in particular difficulties 

in breathing or swallowing, rash, itching, hives or swelling of the face, extremities, eyes, lips and/or 

tongue, dizziness) patients should discontinue treatment and contact the physician (see section 4.4). 

 

Arthralgia has been reported in post-marketing experience. In some cases this occurred as part of a 

hypersensitivity reaction. 

 

Laboratory findings 

In controlled clinical trials, clinically relevant changes in standard laboratory parameters were 

uncommonly associated with the administration of Sprimeo. In clinical studies in hypertensive 

patients, Sprimeo had no clinically important effects on total cholesterol, high density lipoprotein 

cholesterol (HDL-C), fasting triglycerides, fasting glucose or uric acid. 

 

Haemoglobin and haematocrit: Small decreases in haemoglobin and haematocrit (mean decreases of 

approximately 0.05 mmol/l and 0.16 volume percent, respectively) were observed. No patients 

discontinued therapy due to anaemia. This effect is also seen with other agents acting on the renin-

angiotensin system, such as ACEI and ARBs. 

 

Serum potassium: Increases in serum potassium have been observed with aliskiren and these may be 

exacerbated by concomitant use of other agents acting on the RAAS or by NSAIDs. Consistent with 

standard medical practice, periodic determination of renal function including serum electrolytes is 

advised if co-administration is considered necessary. The combination of aliskiren with ARBs or 

ACEIs is contraindicated in patients with diabetes mellitus or renal impairment (GFR 

< 60 ml/min/1.73 m
2
) and is not recommended in other patients (see sections 4.3, 4.4 and 5.1). 

 

In post-marketing experience, renal dysfunction and cases of acute renal failure have been reported in 

patients at risk (see section 4.4). There have also been reports of peripheral oedema, increase in blood 

creatinine and severe cutaneous adverse reactions (SCARs) including toxic epidermal necrolysis 

(TEN) and oral mucosal reactions. 

 

4.9 Overdose 

 

Limited data are available related to overdose in humans. The most likely manifestations of 

overdosage would be hypotension, related to the antihypertensive effect of aliskiren. If symptomatic 

hypotension should occur, supportive treatment should be initiated. 

 

In a study conducted in patients with end stage renal disease (ESRD) receiving haemodialysis, 

dialysis clearance of aliskiren was low (< 2% of oral clearance). Therefore dialysis is not adequate to 

treat aliskiren over-exposure. 

 

 

5. PHARMACOLOGICAL PROPERTIES 

 

5.1 Pharmacodynamic properties 

 

Pharmacotherapeutic group: Renin inhibitor, ATC code: C09XA02 

 

Aliskiren is an orally active, non-peptide, potent and selective direct inhibitor of human renin. 

 

By inhibiting the enzyme renin, aliskiren inhibits the RAAS at the point of activation, blocking the 

conversion of angiotensinogen to angiotensin I and decreasing levels of angiotensin I and angiotensin 

II. Whereas other agents that inhibit the RAAS (ACEI and angiotensin II receptor blockers (ARB)) 

cause a compensatory rise in plasma renin activity (PRA), treatment with aliskiren decreases PRA in 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



9 

hypertensive patients by approximately 50 to 80%. Similar reductions were found when aliskiren was 

combined with other antihypertensive agents. The clinical implications of the differences in effect on 

PRA are not known at the present time. 

 

Hypertension 

In hypertensive patients, once-daily administration of Sprimeo at doses of 150 mg and 300 mg 

provided dose-dependent reductions in both systolic and diastolic blood pressure that were maintained 

over the entire 24-hour dose interval (maintaining benefit in the early morning) with a mean peak to 

trough ratio for diastolic response of up to 98% for the 300 mg dose. 85 to 90% of the maximal blood-

pressure-lowering effect was observed after 2 weeks. The blood-pressure-lowering effect was 

sustained during long-term treatment, and was independent of age, gender, body mass index and 

ethnicity. Sprimeo has been studied in 1,864 patients aged 65 years or older, and in 426 patients aged 

75 years or older. 

 

Sprimeo monotherapy studies have shown blood pressure lowering effects comparable to other classes 

of antihypertensive agents including ACEI and ARB. Compared to a diuretic (hydrochlorothiazide - 

HCTZ), Sprimeo 300 mg lowered systolic/diastolic blood pressure by 17.0/12.3 mmHg, compared to 

14.4/10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment. 

 

Combination therapy studies are available for Sprimeo added to the diuretic hydrochlorothiazide, the 

calcium channel blocker amlodipine and the beta blocker atenolol. These combinations were well 

tolerated. Sprimeo induced an additive blood-pressure-lowering effect when added to 

hydrochlorothiazide. In patients who did not adequately respond to 5 mg of the calcium channel 

blocker amlodipine, the addition of Sprimeo 150 mg had a blood-pressure-lowering effect similar to 

that obtained by increasing amlodipine dose to 10 mg, but had a lower incidence of oedema (aliskiren 

150 mg/amlodipine 5 mg 2.1% vs. amlodipine 10 mg 11.2%). 

 

The efficacy and safety of aliskiren-based therapy were compared to ramipril-based therapy in a 9-

month non-inferiority study in 901 elderly patients (≥ 65 years) with essential systolic hypertension. 

Aliskiren 150 mg or 300 mg per day or ramipril 5 mg or 10 mg per day were administered for 

36 weeks with optional add-on therapy of hydrochlorothiazide (12.5 mg or 25 mg) at week 12, and 

amlodipine (5 mg or 10 mg) at week 22. Over the 12 week period, aliskiren monotherapy lowered 

systolic/diastolic blood pressure by 14.0/5.1 mmHg, compared to 11.6/3.6 mmHg for ramipril, 

consistent with aliskiren being non-inferior to ramipril at the dosages chosen and the differences in 

systolic and diastolic blood pressure were statistically significant. Tolerability was comparable in 

both treatment arms, however cough was more often reported with the ramipril regimen than the 

aliskiren regimen (14.2% vs. 4.4%), whilst diarrhoea was more common with the aliskiren regimen 

than for the ramipril regimen (6.6% vs. 5.0%). 

 

In a 8-week study in 754 hypertensive elderly (≥ 65 years) and very elderly patients (30% ≥ 75 years) 

aliskiren at doses of 75 mg, 150 mg and 300 mg provided statistically significant superior reduction in 

blood pressure (both systolic and diastolic) when compared to placebo. No additional blood pressure 

lowering effect was detected with 300 mg aliskiren compared to 150 mg aliskiren. All three doses 

were well tolerated in both elderly and very elderly patients. 

 

In obese hypertensive patients who did not adequately respond to HCTZ 25 mg, add-on treatment with 

Sprimeo 300 mg provided additional blood pressure reduction that was comparable to add-on 

treatment with irbesartan 300 mg or amlodipine 10 mg. 

 

There has been no evidence of first-dose hypotension and no effect on pulse rate in patients treated in 

controlled clinical studies. Excessive hypotension was uncommonly (0.1%) seen in patients with 

uncomplicated hypertension treated with Sprimeo alone. Hypotension was also uncommon (<1%) 

during combination therapy with other antihypertensive agents. With cessation of treatment, blood 

pressure gradually returned towards baseline levels over a period of several weeks, with no evidence 

of a rebound effect for blood pressure or PRA. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



10 

In a 36-week study involving 820 patients with ischaemic left ventricular dysfunction, no changes in 

ventricular remodelling as assessed by left ventricular end systolic volume were detected with 

aliskiren compared to placebo on top of background therapy. 

 

The combined rates of cardiovascular death, hospitalisation for heart failure, recurrent heart attack, 

stroke and resuscitated sudden death were similar in the aliskiren group and the placebo group. 

However, in patients receiving aliskiren there was a significantly higher rate of hyperkalaemia, 

hypotension and kidney dysfunction when compared to the placebo group. 

 

Aliskiren was evaluated for cardiovascular and/or renal benefit in a double-blind placebo controlled 

randomised trial in 8,606 patients with type 2 diabetes and chronic kidney disease (evidenced by 

proteinuria and/or GFR < 60 ml/min/1.73 m
2
) with or without cardiovascular disease. In most patients 

arterial blood pressure was well controlled at baseline. The primary endpoint was a composite of 

cardiovascular and renal complications. 

 

In this study, aliskiren 300 mg was compared to placebo when added to standard of care which 

included either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker. The 

study was discontinued prematurely because the participants were unlikely to benefit from aliskiren. 

Preliminary study results indicated a hazard ratio for the primary endpoint of 1.09 in favour of 

placebo (95% Confidence Interval: 0.97, 1.22, 2-sided p=0.17). In addition, an increased incidence of 

serious adverse outcomes was observed with aliskiren compared to placebo for renal complications 

(4.7% versus 3.3%), hyperkalaemia (36.9% versus 27.1%), hypotension (18.4% versus 14.6%) and 

stroke (2.7% versus 2.0%). The increased incidence of non-fatal stroke was greater in patients with 

renal insufficiency. 

 

Beneficial effects of Sprimeo on mortality and cardiovascular morbidity and target organ damage are 

currently unknown. 

 

Cardiac electrophysiology 

No effect on QT interval was reported in a randomised, double-blind, placebo, and active-controlled 

study using standard and Holter electrocardiography. 

 

5.2 Pharmacokinetic properties 

 

Absorption 

Following oral absorption, peak plasma concentrations of aliskiren are reached after 1-3 hours. The 

absolute bioavailability of aliskiren is approximately 2-3%. Meals with a high fat content reduce Cmax 

by 85% and AUC by 70%. Steady-state-plasma concentrations are reached within 5-7 days following 

once-daily administration and steady-state levels are approximately 2-fold greater than with the initial 

dose. 

 

Distribution 

Following intravenous administration, the mean volume of distribution at steady state is 

approximately 135 litres, indicating that aliskiren distributes extensively into the extravascular space. 

Aliskiren plasma protein binding is moderate (47-51%) and independent of the concentration. 

 

Metabolism and elimination 

The mean half-life is about 40 hours (range 34-41 hours). Aliskiren is mainly eliminated as unchanged 

compound in the faeces (78%). Approximately 1.4% of the total oral dose is metabolised. The enzyme 

responsible for this metabolism is CYP3A4. Approximately 0.6% of the dose is recovered in urine 

following oral administration. Following intravenous administration, the mean plasma clearance is 

approximately 9 l/h. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



11 

Linearity/non-linearity 

Exposure to aliskiren increased more than in proportion to the increase in dose. After single dose 

administration in the dose range of 75 to 600 mg, a 2-fold increase in dose results in a ~2.3 and 2.6-

fold increase in AUC and Cmax, respectively. At steady state the non-linearity may be more 

pronounced. Mechanisms responsible for deviation from linearity have not been identified. A possible 

mechanism is saturation of transporters at the absorption site or at the hepatobiliary clearance route. 

 

Characteristics in patients 

Aliskiren is an effective once-a-day antihypertensive treatment in adult patients, regardless of gender, 

age, body mass index and ethnicity. 

 

The AUC is 50% higher in elderly (>65 years) than in young subjects. Gender, weight and ethnicity 

have no clinically relevant influence on aliskiren pharmacokinetics. 

 

The pharmacokinetics of aliskiren were evaluated in patients with varying degrees of renal 

insufficiency. Relative AUC and Cmax of aliskiren in subjects with renal impairment ranged between 

0.8 to 2 times the levels in healthy subjects following single dose administration and at steady state. 

These observed changes, however, did not correlate with the severity of renal impairment. No 

adjustment of the initial dosage of Sprimeo is required in patients with mild to moderate renal 

impairment (see sections 4.2 and 4.4). Sprimeo is not recommended in patients with severe renal 

impairment (glomerular filtration rate (GFR) < 30 ml/min/1.73 m
2
). Concomitant use of Sprimeo with 

ARBs or ACEIs is contraindicated in patients with renal impairment (GFR < 60 ml/min/1.73 m
2
) (see 

section 4.3). 

 

The pharmacokinetics of aliskiren were evaluated in patients with end stage renal disease receiving 

haemodialysis. Administration of a single oral dose of 300 mg aliskiren was associated with very 

minor changes in the pharmacokinetics of aliskiren (change in Cmax of less than 1.2 fold; increase in 

AUC of up to 1.6 fold) compared to matched healthy subjects. Timing of haemodialysis did not 

significantly alter the pharmacokinetics of aliskiren in ESRD patients. Therefore, if administration of 

aliskiren in ESRD patients receiving haemodialysis is considered necessary, no dose adjustment is 

warranted in these patients. However, the use of aliskiren is not recommended in patients with severe 

renal impairment (see section 4.4). 

 

The pharmacokinetics of aliskiren were not significantly affected in patients with mild to severe liver 

disease. Consequently, no adjustment of the initial dose of aliskiren is required in patients with mild 

to severe hepatic impairment. 

 

5.3 Preclinical safety data 

 

Carcinogenic potential was assessed in a 2-year rat study and a 6-month transgenic mouse study. No 

carcinogenic potential was detected. One colonic adenoma and one caecal adenocarcinoma recorded 

in rats at the dose of 1,500 mg/kg/day were not statistically significant. Although aliskiren has known 

irritation potential, safety margins obtained in humans at the dose of 300 mg during a study in healthy 

volunteers were considered to be appropriate at 9-11-fold based on faecal concentrations or 6-fold 

based on mucosa concentrations in comparison with 250 mg/kg/day in the rat carcinogenicity study. 

 

Aliskiren was devoid of any mutagenic potential in the in vitro and in vivo mutagenicity studies. The 

assays included in vitro assays in bacterial and mammalian cells and in vivo assessments in rats. 

 

Reproductive toxicity studies with aliskiren did not reveal any evidence of embryofoetal toxicity or 

teratogenicity at doses up to 600 mg/kg/day in rats or 100 mg/kg/day in rabbits. Fertility, pre-natal 

development and post-natal development were unaffected in rats at doses up to 250 mg/kg/day. The 

doses in rats and rabbits provided systemic exposures of 1 to 4 and 5 times higher, respectively, than 

the maximum recommended human dose (300 mg). 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



12 

Safety pharmacology studies did not reveal any adverse effects on central nervous, respiratory or 

cardiovascular function. Findings during repeat-dose toxicity studies in animals were consistent with 

the known local irritation potential or the expected pharmacological effects of aliskiren. 

 

 

6. PHARMACEUTICAL PARTICULARS 

 

6.1 List of excipients 

 

Crospovidone 

Magnesium stearate 

Cellulose, microcrystalline 

Povidone 

Silica, colloidal anhydrous 

Hypromellose 

Macrogol 

Talc 

Iron oxide, black (E 172) 

Iron oxide, red (E 172) 

Titanium dioxide (E 171) 

 

6.2 Incompatibilities 

 

Not applicable 

 

6.3 Shelf life 

 

2 years 

 

6.4 Special precautions for storage 

 

Do not store above 30C. Store in the original package in order to protect from moisture. 

 

6.5 Nature and contents of container 

 

PA/Alu/PVC – Alu blisters: 

Packs containing 7, 14, 28, 30, 50, 56, 84, 90, 98 or 280 tablets. 

Packs containing 84 (3x28), 98 (2x49) or 280 (20x14) tablets are multi-packs. 

 

PVC/polychlorotrifluoroethylene (PCTFE) – Alu blisters: 

Packs containing 14, 28, 30, 50, 56, 90, 98 or 280 tablets. 

Packs containing 98 (2x49) or 280 (20x14) tablets are multi-packs. 

Packs containing 56 and 98 (2x49) tablets are perforated unit-dose blisters. 

 

Not all pack sizes may be marketed. 

 

6.6 Special precautions for disposal 

 

Any unused product or waste material should be disposed of in accordance with local requirements. 

 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



13 

7. MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

West Sussex, RH12 5AB 

United Kingdom 

 

 

8. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/07/407/001-010 

EU/1/07/407/021-030 

 

 

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 

 

22.08.2007 

 

 

10. DATE OF REVISION OF THE TEXT 

 

 

Detailed information on this product is available on the website of the European Medicines Agency 

http://www.ema.europa.eu 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



14 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 300 mg film-coated tablets 

 

 

2. QUALITATIVE AND QUANTITATIVE COMPOSITION 

 

Each film-coated tablet contains 300 mg aliskiren (as hemifumarate). 

 

For a full list of excipients, see section 6.1. 

 

 

3. PHARMACEUTICAL FORM 

 

Film-coated tablet 

 

Light-red, biconvex, ovaloid tablet, imprinted “IU” on one side and “NVR” on the other side. 

 

 

4. CLINICAL PARTICULARS 

 

4.1 Therapeutic indications 

 

Treatment of essential hypertension. 

 

4.2 Posology and method of administration 

 

The recommended dose of Sprimeo is 150 mg once daily. In patients whose blood pressure is not 

adequately controlled, the dose may be increased to 300 mg once daily. 

 

The antihypertensive effect is substantially present within two weeks (85-90%) after initiating therapy 

with 150 mg once daily. 

 

Sprimeo may be used alone or in combination with other antihypertensive agents with the exception 

of use in combination with angiotensin converting enzyme inhibitors (ACEI) or angiotensin II 

receptor blockers (ARB) in patients with diabetes mellitus or renal impairment (glomerular filtration 

rate (GFR) < 60 ml/min/1.73 m
2
) (see sections 4.3, 4.4 and 5.1). 

 

Sprimeo should be taken with a light meal once a day, preferably at the same time each day. 

Grapefruit juice should not be taken together with Sprimeo. 

 

Renal impairment 

No adjustment of the initial dose is required for patients with mild to moderate renal impairment (see 

sections 4.4 and 5.2). Sprimeo is not recommended in patients with severe renal impairment (GFR 

< 30 ml/min/1.73 m
2
). Concomitant use of Sprimeo with ARBs or ACEIs is contraindicated in 

patients with renal impairment (GFR < 60 ml/min/1.73 m
2
) (see section 4.3). 

 

Hepatic impairment 

No adjustment of the initial dose is required for patients with mild to severe hepatic impairment (see 

section 5.2). 

 

Elderly patients (over 65 years) 

The recommended starting dose of aliskiren in elderly patients is 150 mg. No clinically meaningful 

additional blood pressure reduction is observed by increasing the dose to 300 mg in the majority of 

elderly patients. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



15 

Paediatric patients (below 18 years) 

Sprimeo is not recommended for use in children and adolescents below age 18 due to a lack of data on 

safety and efficacy (see section 5.2). 

 

4.3 Contraindications 

 

Hypersensitivity to the active substance or to any of the excipients. 

 

History of angioedema with aliskiren. 

 

Hereditary or idiopathic angioedema. 

 

Second and third trimesters of pregnancy (see section 4.6). 

 

The concomitant use of aliskiren with ciclosporin and itraconazole, two highly potent P-gp inhibitors, 

and other potent P-gp inhibitors (e.g. quinidine), is contraindicated (see section 4.5). 

 

The concomitant use of aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes 

mellitus or renal impairment (GFR < 60 ml/min/1.73 m
2
) (see sections 4.2, 4.4, 4.5 and 5.1). 

 

4.4 Special warnings and precautions for use 

 

Aliskiren should be used with caution in patients with serious congestive heart failure (New York 

Heart Association [NYHA] functional class III-IV). 

 

In the event of severe and persistent diarrhoea, Sprimeo therapy should be stopped. 

 

Dual blockade of the renin-angiotensin-aldosterone system (RAAS) 

Hypotension, syncope, stroke, hyperkalaemia, and changes in renal function (including acute renal 

failure) have been reported in susceptible individuals, especially if combining medicinal products that 

affect this system (see section 5.1). Dual blockade of the renin-angiotensin-aldosterone system by 

combining aliskiren with an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II 

receptor blocker (ARB) is therefore not recommended. 

 

The use of aliskiren in combination with ARBs or ACEIs is contraindicated in patients with diabetes 

mellitus or renal impairment (GFR < 60 ml/min/1.73 m
2
) (see section 4.3). 

 

Angioedema 

As with other agents acting on the renin-angiotensin system, angioedema or symptoms suggestive of 

angioedema (swelling of the face, lips, throat and/or tongue) have been reported in patients treated 

with aliskiren. 

 

A number of these patients had a history of angioedema or symptoms suggestive of angioedema, 

which in some cases followed use of other medicines that can cause angioedema, including RAAS 

blockers (angiotensin converting enzyme inhibitors or angiotensin receptor blockers) (see section 4.8). 

 

Patients with a history of angioedema may be at increased risk of experiencing angioedema during 

treatment with aliskiren (see sections 4.3 and 4.8). Caution should therefore be exercised when 

prescribing aliskiren to patients with a history of angioedema, and such patients should be closely 

monitored during treatment (see section 4.8) especially at the beginning of the treatment. 

 

If angioedema occurs, Sprimeo should be promptly discontinued and appropriate therapy and 

monitoring provided until complete and sustained resolution of signs and symptoms has occurred. 

Where there is involvement of the tongue, glottis or larynx adrenaline should be administered. In 

addition, measures necessary to maintain patent airways should be provided. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



16 

Sodium and/or volume depleted patients 

In patients with marked volume- and/or salt-depletion (e.g. those receiving high doses of diuretics) 

symptomatic hypotension could occur after initiation of treatment with Sprimeo. This condition 

should be corrected prior to administration of Sprimeo, or the treatment should start under close 

medical supervision. 

 

Renal impairment 

In clinical studies Sprimeo has not been investigated in hypertensive patients with severe renal 

impairment (serum creatinine ≥ 150 μmol/l or 1.70 mg/dl in women and ≥ 177 μmol/l or 2.00 mg/dl in 

men and/or estimated GFR < 30 ml/min/1.73 m
2
), history of dialysis, nephrotic syndrome or 

renovascular hypertension. Sprimeo is not recommended in patients with severe renal impairment 

(GFR < 30 ml/min/1.73 m
2
). 

 

As for other agents acting on the renin-angiotensin system, caution should be exercised when aliskiren 

is given in the presence of conditions pre-disposing to kidney dysfunction such as hypovolaemia (eg. 

due to blood loss, severe prolonged diarrhoea, prolonged vomiting, etc.), heart disease, liver disease, 

diabetes mellitus or kidney disease. The concomitant use of aliskiren and ACEIs or ARBs is 

contraindicated in patients with renal impairment (GFR < 60 ml/min/1.73 m
2
). Acute renal failure, 

reversible upon discontinuation of treatment, has been reported in at-risk patients receiving aliskiren 

in post-marketing experience. In the event that any signs of renal failure occur, aliskiren should be 

promptly discontinued. 

 

Increases in serum potassium have been observed with aliskiren in post-marketing experience and 

these may be exacerbated by concomitant use of other agents acting on the RAAS or by non-steroidal 

anti-inflammatory drugs (NSAIDs). Consistent with standard medical practice, periodic determination 

of renal function including serum electrolytes is advised if co-administration is considered necessary. 

 

Renal artery stenosis 

No controlled clinical data are available on the use of Sprimeo in patients with unilateral or bilateral 

renal artery stenosis, or stenosis to a solitary kidney. However, as with other agents acting on the 

renin-angiotensin system, there is an increased risk of renal insufficiency, including acute renal 

failure, when patients with renal artery stenosis are treated with aliskiren. Therefore, caution should 

be exercised in these patients. If renal failure occurs, treatment should be discontinued. 

 

Moderate P-gp inhibitors 

Co-administration of aliskiren 300 mg with ketoconazole 200 mg or verapamil 240 mg resulted in a 

76% or 97% increase in aliskiren AUC, respectively. Therefore caution should be exercised when 

aliskiren is administered with moderate P-gp inhibitors such as ketoconazole or verapamil (see section 

4.5). 

 

4.5 Interaction with other medicinal products and other forms of interaction 

 

The combination of aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes 

mellitus or renal impairment (GFR < 60 ml/min/1.73 m
2
) and is not recommended in other patients 

(see sections 4.3, 4.4 and 5.1). 

 

Compounds that have been investigated in clinical pharmacokinetic studies include acenocoumarol, 

atenolol, celecoxib, pioglitazone, allopurinol, isosorbide-5-mononitrate and hydrochlorothiazide. No 

interactions have been identified. 

 

Co-administration of aliskiren with either metformin (↓28%), amlodipine (↑29%) or cimetidine 

(↑19%) resulted in between 20% and 30% change in Cmax or AUC of Sprimeo. When administered 

with atorvastatin, steady-state Sprimeo AUC and Cmax increased by 50%. Co-administration of 

Sprimeo had no significant impact on atorvastatin, metformin or amlodipine pharmacokinetics. As a 

result no dose adjustment for Sprimeo or these co-administered medicinal products is necessary. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



17 

Digoxin and verapamil bioavailability may be slightly decreased by Sprimeo. 

 

In experimental animals, it has been shown that P-gp is a major determinant of Sprimeo 

bioavailability. Inducers of P-gp (St. John’s wort, rifampicin) might therefore decrease the 

bioavailability of Sprimeo. 

 

CYP450 interactions 

Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A). 

Aliskiren does not induce CYP3A4. Therefore aliskiren is not expected to affect the systemic 

exposure of substances that inhibit, induce or are metabolised by these enzymes. Aliskiren is 

metabolised minimally by the cytochrome P450 enzymes. Hence, interactions due to inhibition or 

induction of CYP450 isoenzymes are not expected. However, CYP3A4 inhibitors often also affect P-

gp. Increased aliskiren exposure during co-administration of CYP3A4 inhibitors that also inhibit P-gp 

can therefore be expected (see P-glycoprotein interactions below). 

 

P-glycoprotein interactions 

MDR1/Mdr1a/1b (P-gp) was found to be the major efflux system involved in intestinal absorption and 

biliary excretion of aliskiren in preclinical studies. Rifampicin, which is an inducer of P-gp, reduced 

aliskiren bioavailability by approximately 50% in a clinical study. Other inducers of P-gp (St. John’s 

wort) might decrease the bioavailability of Sprimeo. Although this has not been investigated for 

aliskiren, it is known that P-gp also controls tissue uptake of a variety of substrates and P-gp 

inhibitors can increase the tissue-to-plasma concentration ratios. Therefore, P-gp inhibitors may 

increase tissue levels more than plasma levels. The potential for drug interactions at the P-gp site will 

likely depend on the degree of inhibition of this transporter. 

 

P-gp potent inhibitors 

A single dose drug interaction study in healthy subjects has shown that ciclosporin (200 and 600 mg) 

increases Cmax of aliskiren 75 mg approximately 2.5-fold and AUC approximately 5-fold. The increase 

may be higher with higher aliskiren doses. In healthy subjects, itraconazole (100 mg) increases AUC 

and Cmax of aliskiren (150 mg) by 6.5-fold and 5.8-fold, respectively. Therefore, concomitant use of 

aliskiren and P-gp potent inhibitors is contraindicated (see section 4.3). 

 

Moderate P-gp inhibitors 

Co-administration of ketoconazole (200 mg) or verapamil (240 mg) with aliskiren (300 mg) resulted 

in a 76% or 97% increase in aliskiren AUC, respectively. The change in plasma levels of aliskiren in 

the presence of ketoconazole or verapamil is expected to be within the range that would be achieved if 

the dose of aliskiren were doubled; aliskiren doses of up to 600 mg, or twice the highest 

recommended therapeutic dose, have been found to be well tolerated in controlled clinical trials. 

Preclinical studies indicate that aliskiren and ketoconazole co-administration enhances aliskiren 

gastrointestinal absorption and decreases biliary excretion. Therefore, caution should be exercised 

when aliskiren is administered with ketoconazole, verapamil or other moderate P-gp inhibitors 

(clarithromycin, telithromycin, erythromycin, amiodarone). 

 

P-gp substrates or weak inhibitors 

No relevant interactions with atenolol, digoxin, amlodipine or cimetidine have been observed. When 

administered with atorvastatin (80 mg), steady-state aliskiren (300 mg) AUC and Cmax increased by 

50%. 

 

Organic anion transporting polypeptide (OATP) inhibitors 

Preclinical studies indicate that aliskiren might be a substrate of organic anion transporting 

polypeptides. Therefore, the potential exists for interactions between OATP inhibitors and aliskiren 

when administered concomitantly (see interaction with Grapefruit juice). 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



18 

Furosemide 

When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced 

by 28% and 49% respectively. It is therefore recommended that the effects be monitored when 

initiating and adjusting furosemide therapy to avoid possible underutilisation in clinical situations of 

volume overload. 

 

Non-steroidal anti-inflammatory drugs (NSAIDs) 

As with other agents acting on the renin-angiotensin system, NSAIDs may reduce the anti-

hypertensive effect of aliskiren. In some patients with compromised renal function (dehydrated 

patients or elderly patients) aliskiren given concomitantly with NSAIDs may result in further 

deterioration of renal function, including possible acute renal failure, which is usually reversible. 

Therefore the combination of aliskiren with an NSAID requires caution, especially in elderly patients. 

 

Medicinal products affecting serum potassium levels 

Concomitant use of other agents affecting the RAAS, of NSAIDs or of agents that increase serum 

potassium levels (e.g. potassium-sparing diuretics, potassium supplements, salt substitutes containing 

potassium, heparin) may lead to increases in serum potassium. If co-medication with an agent 

affecting the level of serum potassium is considered necessary, caution is advisable. The combination 

of aliskiren with ARBs or ACEIs is contraindicated in patients with diabetes mellitus or renal 

impairment (GFR < 60 ml/min/1.73 m
2
) and is not recommended in other patients (see sections 4.3, 

4.4 and 5.1). 

 

Grapefruit juice 

Administration of grapefruit juice with aliskiren resulted in a decrease in AUC and Cmax of aliskiren. 

Co-administration with aliskiren 150 mg resulted in a 61% decrease in aliskiren AUC and co-

administration with aliskiren 300 mg resulted in a 38% decrease in aliskiren AUC. This decrease is 

likely due to an inhibition of organic anion transporting polypeptide-mediated uptake of aliskiren by 

grapefruit juice in the gastrointestinal tract. Therefore, because of the risk of therapeutic failure, 

grapefruit juice should not be taken together with Sprimeo. 

 

Warfarin 

The effects of Sprimeo on warfarin pharmacokinetics have not been evaluated. 

 

Food intake 

Meals with a high fat content have been shown to reduce the absorption of Sprimeo substantially. 

 

4.6 Fertility, pregnancy and lactation 

 

Pregnancy 

There are no data on the use of aliskiren in pregnant women. Sprimeo was not teratogenic in rats or 

rabbits (see section 5.3). Other substances that act directly on the RAAS have been associated with 

serious foetal malformations and neonatal death. As for any medicine that acts directly on the RAAS, 

Sprimeo should not be used during the first trimester of pregnancy or in women planning to become 

pregnant and is contraindicated during the second and third trimesters (see section 4.3). Healthcare 

professionals prescribing any agents acting on the RAAS should counsel women of childbearing 

potential about the potential risk of these agents during pregnancy. If pregnancy is detected during 

therapy, Sprimeo should be discontinued accordingly. 

 

Breast-feeding 

It is not known whether aliskiren is excreted in human milk. Sprimeo was secreted in the milk of 

lactating rats. Its use is therefore not recommended in women who are breast-feeding. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



19 

4.7 Effects on ability to drive and use machines 

 

No studies on the effects on the ability to drive and use machines have been performed. However, 

when driving vehicles or operating machinery it must be borne in mind that dizziness or weariness 

may occasionally occur when taking any antihypertensive therapy. Sprimeo has negligible influence 

on the ability to drive and use machines. 

 

4.8 Undesirable effects 

 

Sprimeo has been evaluated for safety in more than 7,800 patients, including over 2,300 treated for 

over 6 months, and more than 1,200 for over 1 year. The incidence of adverse reactions showed no 

association with gender, age, body mass index, race or ethnicity. Treatment with Sprimeo resulted in 

an overall incidence of adverse reactions similar to placebo up to 300 mg. Adverse reactions have 

generally been mild and transient in nature and have only infrequently required discontinuation of 

therapy. The most common adverse drug reaction is diarrhoea. 

 

The adverse drug reactions (Table 1) are ranked under heading of frequency, the most frequent first, 

using the following convention: very common (≥1/10); common (≥1/100, <1/10); uncommon 

(≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000); very rare (<1/10,000) and not known (cannot be 

estimated from the available data). Within each frequency grouping, undesirable effects are presented 

in order of decreasing seriousness. 

 

Table 1 

 

Nervous system disorders 

 Common: Dizziness 

Vascular disorders 

 Uncommon: Hypotension 

Gastrointestinal disorders 

 Common: Diarrhoea 

Immune system disorders 

 Rare: Hypersensitivity reactions 

Skin and subcutaneous tissue disorders 

 Uncommon: Rash, severe cutaneous adverse reactions (SCARs) including toxic 

epidermal necrolysis (TEN) and oral mucosal reactions 

 Rare: Angioedema 

Musculoskeletal and connective tissue disorders 

 Common: Arthralgia 

Renal and urinary disorders 

 Uncommon: Acute renal failure, renal impairment 

General disorders and administration site conditions 

 Uncommon: Oedema peripheral 

Investigations 

 Common: Hyperkalaemia 

 Rare: Haemoglobin decreased, haematocrit decreased 

 Rare: Blood creatinine increased 

 

Angioedema and hypersensitivity reactions have occurred during treatment with aliskiren. In 

controlled clinical trials, angioedema and hypersensitivity reactions occurred rarely during treatment 

with aliskiren with rates comparable to treatment with placebo or comparators. 

 

Cases of angioedema or symptoms suggestive of angioedema (swelling of the face, lips, throat and/or 

tongue) have also been reported in post-marketing experience. A number of these patients had a 

history of angioedema or symptoms suggestive of angioedema which in some cases was associated 

with the administration of other medicines known to cause angioedema, including RAAS blockers 

(ACE inhibitors or ARBs). 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



20 

 

Hypersensitivity reactions have also been reported in post-marketing experience. 

 

In the event of any signs suggesting a hypersensitivity reaction/angioedema (in particular difficulties 

in breathing or swallowing, rash, itching, hives or swelling of the face, extremities, eyes, lips and/or 

tongue, dizziness) patients should discontinue treatment and contact the physician (see section 4.4). 

 

Arthralgia has been reported in post-marketing experience. In some cases this occurred as part of a 

hypersensitivity reaction. 

 

Laboratory findings 

In controlled clinical trials, clinically relevant changes in standard laboratory parameters were 

uncommonly associated with the administration of Sprimeo. In clinical studies in hypertensive 

patients, Sprimeo had no clinically important effects on total cholesterol, high density lipoprotein 

cholesterol (HDL-C), fasting triglycerides, fasting glucose or uric acid. 

 

Haemoglobin and haematocrit: Small decreases in haemoglobin and haematocrit (mean decreases of 

approximately 0.05 mmol/l and 0.16 volume percent, respectively) were observed. No patients 

discontinued therapy due to anaemia. This effect is also seen with other agents acting on the renin-

angiotensin system, such as ACEI and ARBs. 

 

Serum potassium: Increases in serum potassium have been observed with aliskiren and these may be 

exacerbated by concomitant use of other agents acting on the RAAS or by NSAIDs. Consistent with 

standard medical practice, periodic determination of renal function including serum electrolytes is 

advised if co-administration is considered necessary. The combination of aliskiren with ARBs or 

ACEIs is contraindicated in patients with diabetes mellitus or renal impairment (GFR 

< 60 ml/min/1.73 m
2
) and is not recommended in other patients (see sections 4.3, 4.4 and 5.1). 

 

In post-marketing experience, renal dysfunction and cases of acute renal failure have been reported in 

patients at risk (see section 4.4). There have also been reports of peripheral oedema, increase in blood 

creatinine and severe cutaneous adverse reactions (SCARs) including toxic epidermal necrolysis 

(TEN) and oral mucosal reactions. 

 

4.9 Overdose 

 

Limited data are available related to overdose in humans. The most likely manifestations of 

overdosage would be hypotension, related to the antihypertensive effect of aliskiren. If symptomatic 

hypotension should occur, supportive treatment should be initiated. 

 

In a study conducted in patients with end stage renal disease (ESRD) receiving haemodialysis, 

dialysis clearance of aliskiren was low (< 2% of oral clearance). Therefore dialysis is not adequate to 

treat aliskiren over-exposure. 

 

 

5. PHARMACOLOGICAL PROPERTIES 

 

5.1 Pharmacodynamic properties 

 

Pharmacotherapeutic group: Renin inhibitor, ATC code: C09XA02 

 

Aliskiren is an orally active, non-peptide, potent and selective direct inhibitor of human renin. 

 

By inhibiting the enzyme renin, aliskiren inhibits the RAAS at the point of activation, blocking the 

conversion of angiotensinogen to angiotensin I and decreasing levels of angiotensin I and angiotensin 

II. Whereas other agents that inhibit the RAAS (ACEI and angiotensin II receptor blockers (ARB)) 

cause a compensatory rise in plasma renin activity (PRA), treatment with aliskiren decreases PRA in 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



21 

hypertensive patients by approximately 50 to 80%. Similar reductions were found when aliskiren was 

combined with other antihypertensive agents. The clinical implications of the differences in effect on 

PRA are not known at the present time. 

 

Hypertension 

In hypertensive patients, once-daily administration of Sprimeo at doses of 150 mg and 300 mg 

provided dose-dependent reductions in both systolic and diastolic blood pressure that were maintained 

over the entire 24-hour dose interval (maintaining benefit in the early morning) with a mean peak to 

trough ratio for diastolic response of up to 98% for the 300 mg dose. 85 to 90% of the maximal blood-

pressure-lowering effect was observed after 2 weeks. The blood-pressure-lowering effect was 

sustained during long-term treatment, and was independent of age, gender, body mass index and 

ethnicity. Sprimeo has been studied in 1,864 patients aged 65 years or older, and in 426 patients aged 

75 years or older. 

 

Sprimeo monotherapy studies have shown blood pressure lowering effects comparable to other classes 

of antihypertensive agents including ACEI and ARB. Compared to a diuretic (hydrochlorothiazide - 

HCTZ), Sprimeo 300 mg lowered systolic/diastolic blood pressure by 17.0/12.3 mmHg, compared to 

14.4/10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment. 

 

Combination therapy studies are available for Sprimeo added to the diuretic hydrochlorothiazide, the 

calcium channel blocker amlodipine and the beta blocker atenolol. These combinations were well 

tolerated. Sprimeo induced an additive blood-pressure-lowering effect when added to 

hydrochlorothiazide. In patients who did not adequately respond to 5 mg of the calcium channel 

blocker amlodipine, the addition of Sprimeo 150 mg had a blood-pressure-lowering effect similar to 

that obtained by increasing amlodipine dose to 10 mg, but had a lower incidence of oedema (aliskiren 

150 mg/amlodipine 5 mg 2.1% vs. amlodipine 10 mg 11.2%). 

 

The efficacy and safety of aliskiren-based therapy were compared to ramipril-based therapy in a 9-

month non-inferiority study in 901 elderly patients (≥ 65 years) with essential systolic hypertension. 

Aliskiren 150 mg or 300 mg per day or ramipril 5 mg or 10 mg per day were administered for 

36 weeks with optional add-on therapy of hydrochlorothiazide (12.5 mg or 25 mg) at week 12, and 

amlodipine (5 mg or 10 mg) at week 22. Over the 12 week period, aliskiren monotherapy lowered 

systolic/diastolic blood pressure by 14.0/5.1 mmHg, compared to 11.6/3.6 mmHg for ramipril, 

consistent with aliskiren being non-inferior to ramipril at the dosages chosen and the differences in 

systolic and diastolic blood pressure were statistically significant. Tolerability was comparable in 

both treatment arms, however cough was more often reported with the ramipril regimen than the 

aliskiren regimen (14.2% vs. 4.4%), whilst diarrhoea was more common with the aliskiren regimen 

than for the ramipril regimen (6.6% vs. 5.0%). 

 

In a 8-week study in 754 hypertensive elderly (≥ 65 years) and very elderly patients (30% ≥ 75 years) 

aliskiren at doses of 75 mg, 150 mg and 300 mg provided statistically significant superior reduction in 

blood pressure (both systolic and diastolic) when compared to placebo. No additional blood pressure 

lowering effect was detected with 300 mg aliskiren compared to 150 mg aliskiren. All three doses 

were well tolerated in both elderly and very elderly patients. 

 

In obese hypertensive patients who did not adequately respond to HCTZ 25 mg, add-on treatment with 

Sprimeo 300 mg provided additional blood pressure reduction that was comparable to add-on 

treatment with irbesartan 300 mg or amlodipine 10 mg. 

 

There has been no evidence of first-dose hypotension and no effect on pulse rate in patients treated in 

controlled clinical studies. Excessive hypotension was uncommonly (0.1%) seen in patients with 

uncomplicated hypertension treated with Sprimeo alone. Hypotension was also uncommon (<1%) 

during combination therapy with other antihypertensive agents. With cessation of treatment, blood 

pressure gradually returned towards baseline levels over a period of several weeks, with no evidence 

of a rebound effect for blood pressure or PRA. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



22 

In a 36-week study involving 820 patients with ischaemic left ventricular dysfunction, no changes in 

ventricular remodelling as assessed by left ventricular end systolic volume were detected with 

aliskiren compared to placebo on top of background therapy. 

 

The combined rates of cardiovascular death, hospitalisation for heart failure, recurrent heart attack, 

stroke and resuscitated sudden death were similar in the aliskiren group and the placebo group. 

However, in patients receiving aliskiren there was a significantly higher rate of hyperkalaemia, 

hypotension and kidney dysfunction when compared to the placebo group. 

 

Aliskiren was evaluated for cardiovascular and/or renal benefit in a double-blind placebo controlled 

randomised trial in 8,606 patients with type 2 diabetes and chronic kidney disease (evidenced by 

proteinuria and/or GFR < 60 ml/min/1.73 m
2
) with or without cardiovascular disease. In most patients 

arterial blood pressure was well controlled at baseline. The primary endpoint was a composite of 

cardiovascular and renal complications. 

 

In this study, aliskiren 300 mg was compared to placebo when added to standard of care which 

included either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker. The 

study was discontinued prematurely because the participants were unlikely to benefit from aliskiren. 

Preliminary study results indicated a hazard ratio for the primary endpoint of 1.09 in favour of 

placebo (95% Confidence Interval: 0.97, 1.22, 2-sided p=0.17). In addition, an increased incidence of 

serious adverse outcomes was observed with aliskiren compared to placebo for renal complications 

(4.7% versus 3.3%), hyperkalaemia (36.9% versus 27.1%), hypotension (18.4% versus 14.6%) and 

stroke (2.7% versus 2.0%). The increased incidence of non-fatal stroke was greater in patients with 

renal insufficiency. 

 

Beneficial effects of Sprimeo on mortality and cardiovascular morbidity and target organ damage are 

currently unknown. 

 

Cardiac electrophysiology 

No effect on QT interval was reported in a randomised, double-blind, placebo, and active-controlled 

study using standard and Holter electrocardiography. 

 

5.2 Pharmacokinetic properties 

 

Absorption 

Following oral absorption, peak plasma concentrations of aliskiren are reached after 1-3 hours. The 

absolute bioavailability of aliskiren is approximately 2-3%. Meals with a high fat content reduce Cmax 

by 85% and AUC by 70%. Steady-state-plasma concentrations are reached within 5-7 days following 

once-daily administration and steady-state levels are approximately 2-fold greater than with the initial 

dose. 

 

Distribution 

Following intravenous administration, the mean volume of distribution at steady state is 

approximately 135 litres, indicating that aliskiren distributes extensively into the extravascular space. 

Aliskiren plasma protein binding is moderate (47-51%) and independent of the concentration. 

 

Metabolism and elimination 

The mean half-life is about 40 hours (range 34-41 hours). Aliskiren is mainly eliminated as unchanged 

compound in the faeces (78%). Approximately 1.4% of the total oral dose is metabolised. The enzyme 

responsible for this metabolism is CYP3A4. Approximately 0.6% of the dose is recovered in urine 

following oral administration. Following intravenous administration, the mean plasma clearance is 

approximately 9 l/h. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



23 

Linearity/non-linearity 

Exposure to aliskiren increased more than in proportion to the increase in dose. After single dose 

administration in the dose range of 75 to 600 mg, a 2-fold increase in dose results in a ~2.3 and 2.6-

fold increase in AUC and Cmax, respectively. At steady state the non-linearity may be more 

pronounced. Mechanisms responsible for deviation from linearity have not been identified. A possible 

mechanism is saturation of transporters at the absorption site or at the hepatobiliary clearance route. 

 

Characteristics in patients 

Aliskiren is an effective once-a-day antihypertensive treatment in adult patients, regardless of gender, 

age, body mass index and ethnicity. 

 

The AUC is 50% higher in elderly (>65 years) than in young subjects. Gender, weight and ethnicity 

have no clinically relevant influence on aliskiren pharmacokinetics. 

 

The pharmacokinetics of aliskiren were evaluated in patients with varying degrees of renal 

insufficiency. Relative AUC and Cmax of aliskiren in subjects with renal impairment ranged between 

0.8 to 2 times the levels in healthy subjects following single dose administration and at steady state. 

These observed changes, however, did not correlate with the severity of renal impairment. No 

adjustment of the initial dosage of Sprimeo is required in patients with mild to moderate renal 

impairment (see sections 4.2 and 4.4). Sprimeo is not recommended in patients with severe renal 

impairment (glomerular filtration rate (GFR) < 30 ml/min/1.73 m
2
). Concomitant use of Sprimeo with 

ARBs or ACEIs is contraindicated in patients with renal impairment (GFR < 60 ml/min/1.73 m
2
) (see 

section 4.3). 

 

The pharmacokinetics of aliskiren were evaluated in patients with end stage renal disease receiving 

haemodialysis. Administration of a single oral dose of 300 mg aliskiren was associated with very 

minor changes in the pharmacokinetics of aliskiren (change in Cmax of less than 1.2 fold; increase in 

AUC of up to 1.6 fold) compared to matched healthy subjects. Timing of haemodialysis did not 

significantly alter the pharmacokinetics of aliskiren in ESRD patients. Therefore, if administration of 

aliskiren in ESRD patients receiving haemodialysis is considered necessary, no dose adjustment is 

warranted in these patients. However, the use of aliskiren is not recommended in patients with severe 

renal impairment (see section 4.4). 

 

The pharmacokinetics of aliskiren were not significantly affected in patients with mild to severe liver 

disease. Consequently, no adjustment of the initial dose of aliskiren is required in patients with mild 

to severe hepatic impairment. 

 

5.3 Preclinical safety data 

 

Carcinogenic potential was assessed in a 2-year rat study and a 6-month transgenic mouse study. No 

carcinogenic potential was detected. One colonic adenoma and one caecal adenocarcinoma recorded 

in rats at the dose of 1,500 mg/kg/day were not statistically significant. Although aliskiren has known 

irritation potential, safety margins obtained in humans at the dose of 300 mg during a study in healthy 

volunteers were considered to be appropriate at 9-11-fold based on faecal concentrations or 6-fold 

based on mucosa concentrations in comparison with 250 mg/kg/day in the rat carcinogenicity study. 

 

Aliskiren was devoid of any mutagenic potential in the in vitro and in vivo mutagenicity studies. The 

assays included in vitro assays in bacterial and mammalian cells and in vivo assessments in rats. 

 

Reproductive toxicity studies with aliskiren did not reveal any evidence of embryofoetal toxicity or 

teratogenicity at doses up to 600 mg/kg/day in rats or 100 mg/kg/day in rabbits. Fertility, pre-natal 

development and post-natal development were unaffected in rats at doses up to 250 mg/kg/day. The 

doses in rats and rabbits provided systemic exposures of 1 to 4 and 5 times higher, respectively, than 

the maximum recommended human dose (300 mg). 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



24 

Safety pharmacology studies did not reveal any adverse effects on central nervous, respiratory or 

cardiovascular function. Findings during repeat-dose toxicity studies in animals were consistent with 

the known local irritation potential or the expected pharmacological effects of aliskiren. 

 

 

6. PHARMACEUTICAL PARTICULARS 

 

6.1 List of excipients 

 

Crospovidone 

Magnesium stearate 

Cellulose, microcrystalline 

Povidone 

Silica, colloidal anhydrous 

Hypromellose 

Macrogol 

Talc 

Iron oxide, black (E 172) 

Iron oxide, red (E 172) 

Titanium dioxide (E 171) 

 

6.2 Incompatibilities 

 

Not applicable 

 

6.3 Shelf life 

 

2 years 

 

6.4 Special precautions for storage 

 

Do not store above 30C. Store in the original package in order to protect from moisture. 

 

6.5 Nature and contents of container 

 

PA/Alu/PVC – Alu blisters: 

Packs containing 7, 14, 28, 30, 50, 56, 84, 90, 98 or 280 tablets. 

Packs containing 84 (3x28), 90 (3x30), 98 (2x49) or 280 (20x14) tablets are multi-packs. 

 

PVC/polychlorotrifluoroethylene (PCTFE) – Alu blisters: 

Packs containing 14, 28, 30, 50, 56, 90, 98 or 280 tablets. 

Packs containing 98 (2x49) or 280 (20x14) tablets are multi-packs. 

Packs containing 56 and 98 (2x49) tablets are perforated unit-dose blisters. 

 

Not all pack sizes may be marketed. 

 

6.6 Special precautions for disposal 

 

Any unused product or waste material should be disposed of in accordance with local requirements. 

 

 

7. MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



25 

West Sussex, RH12 5AB 

United Kingdom 

 

 

8. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/07/407/011-020 

EU/1/07/407/031-040 

 

 

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 

 

22.08.2007 

 

 

10. DATE OF REVISION OF THE TEXT 

 

 

Detailed information on this product is available on the website of the European Medicines Agency 

http://www.ema.europa.eu 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



26 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX II 

 

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 

 

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY 

AND USE 

 

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 

AUTHORISATION 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



27 

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 

 

Name and address of the manufacturer responsible for batch release 

 

Novartis Farma S.p.A. 

Via Provinciale Schito 131 

I-80058 Torre Annunziata/NA 

Italy 

 

 

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 

 

Medicinal product subject to medical prescription. 

 

 

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 

AUTHORISATION 

 

Pharmacovigilance system 

The MAH must ensure that the system of pharmacovigilance, presented in Module 1.8.1 of the 

Marketing Authorisation, is in place and functioning before and whilst the medicinal product is on the 

market. 

 

Risk Management Plan (RMP) 

The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan, as 

agreed in the RMP presented in Module 1.8.2 of the Marketing Authorisation and any subsequent 

updates of the RMP agreed by the Committee for Medicinal Products for Human Use (CHMP). 

 

As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the 

updated RMP should be submitted at the same time as the next Periodic Safety Update Report 

(PSUR). 

 

In addition, an updated RMP should be submitted: 

 When new information is received that may impact on the current Safety Specification, 

Pharmacovigilance Plan or risk minimisation activities. 

 Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being 

reached. 

 At the request of the European Medicines Agency. 

 

 CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 

EFFECTIVE USE OF THE MEDICINAL PRODUCT 

 

Not applicable. 

 

 OBLIGATION TO CONDUCT POST-AUTHORISATION MEASURES 

 

The MAH shall complete, within the stated timeframe, the following measures: 

 

Description Due date 

The MAH shall submit the final results and study report for the active treatment 

phase of the ALTITUDE study when available 

31 July 2012 

The MAH shall submit an updated risk management plan (RMP) that 

adequately describes all the safety concerns, the pharmacovigilance activities 

and the interventions designed to identify, characterise, prevent or minimise the 

risks. 

Within a month 

following the 

Commission 

Decision 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



28 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX III 

 

LABELLING AND PACKAGE LEAFLET 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



29 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

A. LABELLING 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



30 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

FOLDING BOX FOR UNIT PACK CONTAINING PA/ALU/PVC BLISTERS 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 150 mg film-coated tablets 

Aliskiren 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each film-coated tablet contains 150 mg aliskiren (as hemifumarate). 

 

 

3. LIST OF EXCIPIENTS 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

7 film-coated tablets 

14 film-coated tablets 

28 film-coated tablets 

30 film-coated tablets 

50 film-coated tablets 

56 film-coated tablets 

90 film-coated tablets 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

Oral use. 

Read the package leaflet before use. 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE REACH AND SIGHT OF CHILDREN 

 

Keep out of the reach and sight of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



31 

 

9. SPECIAL STORAGE CONDITIONS 

 

Do not store above 30°C. 

Store in the original package in order to protect from moisture. 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

West Sussex, RH12 5AB 

United Kingdom 

 

 

12. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/07/407/001  7 film-coated tablets 

EU/1/07/407/002  14 film-coated tablets 

EU/1/07/407/003  28 film-coated tablets 

EU/1/07/407/004  30 film-coated tablets 

EU/1/07/407/005  50 film-coated tablets 

EU/1/07/407/006  56 film-coated tablets 

EU/1/07/407/008  90 film-coated tablets 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

Medicinal product subject to medical prescription. 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

Sprimeo 150 mg 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



32 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

FOLDING BOX FOR UNIT PACK CONTAINING PCTFE/PVC BLISTERS 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 150 mg film-coated tablets 

Aliskiren 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each film-coated tablet contains 150 mg aliskiren (as hemifumarate). 

 

 

3. LIST OF EXCIPIENTS 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

14 film-coated tablets 

28 film-coated tablets 

30 film-coated tablets 

50 film-coated tablets 

56 film-coated tablets 

90 film-coated tablets 

98 film-coated tablets 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

Oral use. 

Read the package leaflet before use. 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE REACH AND SIGHT OF CHILDREN 

 

Keep out of the reach and sight of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



33 

 

9. SPECIAL STORAGE CONDITIONS 

 

Do not store above 30°C. 

Store in the original package in order to protect from moisture. 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

West Sussex, RH12 5AB 

United Kingdom 

 

 

12. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/07/407/021 14 film-coated tablets 

EU/1/07/407/022 28 film-coated tablets 

EU/1/07/407/023 30 film-coated tablets 

EU/1/07/407/024 50 film-coated tablets 

EU/1/07/407/025 56 film-coated tablets 

EU/1/07/407/026 56 film-coated tablets (perforated unit-dose blister) 

EU/1/07/407/027 90 film-coated tablets 

EU/1/07/407/028 98 film-coated tablets 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

Medicinal product subject to medical prescription. 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

Sprimeo 150 mg 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



34 

 

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS 

 

BLISTER 

BLISTER (CALENDAR) 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 150 mg film-coated tablets 

Aliskiren 

 

 

2. NAME OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 
 

 

3. EXPIRY DATE 

 

EXP 

 

 

4. BATCH NUMBER 

 

Lot 

 

 

5. OTHER 

 

Monday 

Tuesday 

Wednesday 

Thursday 

Friday 

Saturday 

Sunday 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



35 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX) CONTAINING 

PA/ALU/PVC BLISTERS 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 150 mg film-coated tablets 

Aliskiren 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each film-coated tablet contains 150 mg aliskiren (as hemifumarate). 

 

 

3. LIST OF EXCIPIENTS 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

14 film-coated tablets 

Component of a multipack comprising 20 packs, each containing 14 tablets. 

28 film-coated tablets 

Component of a multipack comprising 3 packs, each containing 28 tablets. 

49 film-coated tablets 

Component of a multipack comprising 2 packs, each containing 49 tablets. 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

Oral use. 

Read the package leaflet before use. 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE REACH AND SIGHT OF CHILDREN 

 

Keep out of the reach and sight of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



36 

 

9. SPECIAL STORAGE CONDITIONS 

 

Do not store above 30°C. 

Store in the original package in order to protect from moisture. 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

West Sussex, RH12 5AB 

United Kingdom 
 

 

12. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/07/407/007  84 film-coated tablets (3x28) 

EU/1/07/407/009  98 film-coated tablets (2x49) 

EU/1/07/407/010  280 film-coated tablets (20x14) 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

Medicinal product subject to medical prescription. 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

Sprimeo 150 mg 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



37 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

OUTER CARTON OF MULTIPACKS (INCLUDING BLUE BOX) CONTAINING 

PA/ALU/PVC BLISTERS 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 150 mg film-coated tablets 

Aliskiren 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each film-coated tablet contains 150 mg aliskiren (as hemifumarate). 

 

 

3. LIST OF EXCIPIENTS 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

84 film-coated tablets 

Multipack comprising 3 packs, each containing 28 tablets. 

98 film-coated tablets 

Multipack comprising 2 packs, each containing 49 tablets. 

280 film-coated tablets 

Multipack comprising 20 packs, each containing 14 tablets. 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

Oral use. 

Read the package leaflet before use. 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE REACH AND SIGHT OF CHILDREN 

 

Keep out of the reach and sight of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



38 

 

9. SPECIAL STORAGE CONDITIONS 

 

Do not store above 30°C. 

Store in the original package in order to protect from moisture. 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

West Sussex, RH12 5AB 

United Kingdom 

 

 

12. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/07/407/007  84 film-coated tablets (3x28) 

EU/1/07/407/009  98 film-coated tablets (2x49) 

EU/1/07/407/010  280 film-coated tablets (20x14) 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

Medicinal product subject to medical prescription. 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

Sprimeo 150 mg 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



39 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX) CONTAINING 

PCTFE/PVC BLISTERS 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 150 mg film-coated tablets 

Aliskiren 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each film-coated tablet contains 150 mg aliskiren (as hemifumarate). 

 

 

3. LIST OF EXCIPIENTS 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

14 film-coated tablets 

Component of a multipack comprising 20 packs, each containing 14 tablets. 

49 film-coated tablets 

Component of a multipack comprising 2 packs, each containing 49 tablets. 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

Oral use. 

Read the package leaflet before use. 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE REACH AND SIGHT OF CHILDREN 

 

Keep out of the reach and sight of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

 

9. SPECIAL STORAGE CONDITIONS 

 

Do not store above 30°C. 

Store in the original package in order to protect from moisture. 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



40 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

West Sussex, RH12 5AB 

United Kingdom 

 

 

12. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/07/407/029 98 film-coated tablets (2x49) (perforated unit-dose blister) 

EU/1/07/407/030 280 film-coated tablets (20x14) 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

Medicinal product subject to medical prescription. 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

Sprimeo 150 mg 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



41 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

OUTER CARTON OF MULTIPACKS (INCLUDING BLUE BOX) CONTAINING 

PCTFE/PVC BLISTERS 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 150 mg film-coated tablets 

Aliskiren 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each film-coated tablet contains 150 mg aliskiren (as hemifumarate). 

 

 

3. LIST OF EXCIPIENTS 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

280 film-coated tablets 

Multipack comprising 20 packs, each containing 14 tablets. 

98 film-coated tablets 

Multipack comprising 2 packs, each containing 49 tablets. 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

Oral use. 

Read the package leaflet before use. 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE REACH AND SIGHT OF CHILDREN 

 

Keep out of the reach and sight of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

 

9. SPECIAL STORAGE CONDITIONS 

 

Do not store above 30°C. 

Store in the original package in order to protect from moisture. 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



42 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

West Sussex, RH12 5AB 

United Kingdom 

 

 

12. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/07/407/029 98 film-coated tablets (2x49) (perforated unit-dose blister) 

EU/1/07/407/030 280 film-coated tablets (20x14) 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

Medicinal product subject to medical prescription. 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

Sprimeo 150 mg 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



43 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

FOLDING BOX FOR UNIT PACK CONTAINING PA/ALU/PVC BLISTERS 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 300 mg film-coated tablets 

Aliskiren 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each film-coated tablet contains 300 mg aliskiren (as hemifumarate). 

 

 

3. LIST OF EXCIPIENTS 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

7 film-coated tablets 

14 film-coated tablets 

28 film-coated tablets 

30 film-coated tablets 

50 film-coated tablets 

56 film-coated tablets 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

Oral use. 

Read the package leaflet before use. 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE REACH AND SIGHT OF CHILDREN 

 

Keep out of the reach and sight of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



44 

 

9. SPECIAL STORAGE CONDITIONS 

 

Do not store above 30°C. 

Store in the original package in order to protect from moisture. 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

West Sussex, RH12 5AB 

United Kingdom 

 

 

12. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/07/407/011  7 film-coated tablets 

EU/1/07/407/012  14 film-coated tablets 

EU/1/07/407/013  28 film-coated tablets 

EU/1/07/407/014  30 film-coated tablets 

EU/1/07/407/015  50 film-coated tablets 

EU/1/07/407/016  56 film-coated tablets 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

Medicinal product subject to medical prescription. 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

Sprimeo 300 mg 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



45 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

FOLDING BOX FOR UNIT PACK CONTAINING PCTFE/PVC BLISTERS 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 300 mg film-coated tablets 

Aliskiren 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each film-coated tablet contains 300 mg aliskiren (as hemifumarate). 

 

 

3. LIST OF EXCIPIENTS 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

14 film-coated tablets 

28 film-coated tablets 

30 film-coated tablets 

50 film-coated tablets 

56 film-coated tablets 

90 film-coated tablets 

98 film-coated tablets 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

Oral use. 

Read the package leaflet before use. 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE REACH AND SIGHT OF CHILDREN 

 

Keep out of the reach and sight of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



46 

 

9. SPECIAL STORAGE CONDITIONS 

 

Do not store above 30°C. 

Store in the original package in order to protect from moisture. 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

West Sussex, RH12 5AB 

United Kingdom 

 

 

12. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/07/407/031 14 film-coated tablets 

EU/1/07/407/032 28 film-coated tablets 

EU/1/07/407/033 30 film-coated tablets 

EU/1/07/407/034 50 film-coated tablets 

EU/1/07/407/035 56 film-coated tablets 

EU/1/07/407/036 56 film-coated tablets (perforated unit-dose blister) 

EU/1/07/407/037 90 film-coated tablets 

EU/1/07/407/038 98 film-coated tablets 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

Medicinal product subject to medical prescription. 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

Sprimeo 300 mg 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



47 

 

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS 

 

BLISTER 

BLISTER (CALENDAR) 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 300 mg film-coated tablets 

Aliskiren 

 

 

2. NAME OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 
 

 

3. EXPIRY DATE 

 

EXP 

 

 

4. BATCH NUMBER 

 

Lot 

 

 

5. OTHER 

 

Monday 

Tuesday 

Wednesday 

Thursday 

Friday 

Saturday 

Sunday 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



48 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX) CONTAINING 

PA/ALU/PVC BLISTERS 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 300 mg film-coated tablets 

Aliskiren 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each film-coated tablet contains 300 mg aliskiren (as hemifumarate). 

 

 

3. LIST OF EXCIPIENTS 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

14 film-coated tablets 

Component of a multipack comprising 20 packs, each containing 14 tablets. 

28 film-coated tablets 

Component of a multipack comprising 3 packs, each containing 28 tablets. 

30 film-coated tablets 

Component of a multipack comprising 3 packs, each containing 30 tablets. 

49 film-coated tablets 

Component of a multipack comprising 2 packs, each containing 49 tablets. 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

Oral use. 

Read the package leaflet before use. 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE REACH AND SIGHT OF CHILDREN 

 

Keep out of the reach and sight of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



49 

 

9. SPECIAL STORAGE CONDITIONS 

 

Do not store above 30°C. 

Store in the original package in order to protect from moisture. 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

West Sussex, RH12 5AB 

United Kingdom 
 

 

12. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/07/407/017  84 film-coated tablets (3x28) 

EU/1/07/407/018  90 film-coated tablets (3x30) 

EU/1/07/407/019  98 film-coated tablets (2x49) 

EU/1/07/407/020  280 film-coated tablets (20x14) 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

Medicinal product subject to medical prescription. 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

Sprimeo 300 mg 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



50 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

OUTER CARTON OF MULTIPACKS (INCLUDING BLUE BOX) CONTAINING 

PA/ALU/PVC BLISTERS 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 300 mg film-coated tablets 

Aliskiren 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each film-coated tablet contains 300 mg aliskiren (as hemifumarate). 

 

 

3. LIST OF EXCIPIENTS 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

84 film-coated tablets 

Multipack comprising 3 packs, each containing 28 tablets. 

90 film-coated tablets 

Multipack comprising 3 packs, each containing 30 tablets. 

98 film-coated tablets 

Multipack comprising 2 packs, each containing 49 tablets. 

280 film-coated tablets 

Multipack comprising 20 packs, each containing 14 tablets. 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

Oral use. 

Read the package leaflet before use. 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE REACH AND SIGHT OF CHILDREN 

 

Keep out of the reach and sight of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



51 

 

9. SPECIAL STORAGE CONDITIONS 

 

Do not store above 30°C. 

Store in the original package in order to protect from moisture. 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

West Sussex, RH12 5AB 

United Kingdom 

 

 

12. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/07/407/017  84 film-coated tablets (3x28) 

EU/1/07/407/018  90 film-coated tablets (3x30) 

EU/1/07/407/019  98 film-coated tablets (2x49) 

EU/1/07/407/020  280 film-coated tablets (20x14) 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

Medicinal product subject to medical prescription. 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

Sprimeo 300 mg 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



52 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

INTERMEDIATE CARTON OF MULTIPACKS (WITHOUT BLUE BOX) CONTAINING 

PCTFE/PVC BLISTERS 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 300 mg film-coated tablets 

Aliskiren 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each film-coated tablet contains 300 mg aliskiren (as hemifumarate). 

 

 

3. LIST OF EXCIPIENTS 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

14 film-coated tablets 

Component of a multipack comprising 20 packs, each containing 14 tablets. 

49 film-coated tablets 

Component of a multipack comprising 2 packs, each containing 49 tablets. 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

Oral use. 

Read the package leaflet before use. 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE REACH AND SIGHT OF CHILDREN 

 

Keep out of the reach and sight of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

 

9. SPECIAL STORAGE CONDITIONS 

 

Do not store above 30°C. 

Store in the original package in order to protect from moisture. 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



53 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

West Sussex, RH12 5AB 

United Kingdom 

 

 

12. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/07/407/039 98 film-coated tablets (2x49) (perforated unit-dose blister) 

EU/1/07/407/040 280 film-coated tablets (20x14) 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

Medicinal product subject to medical prescription. 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

Sprimeo 300 mg 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



54 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

OUTER CARTON OF MULTIPACKS (INCLUDING BLUE BOX) CONTAINING 

PCTFE/PVC BLISTERS 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

Sprimeo 300 mg film-coated tablets 

Aliskiren 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE(S) 

 

Each film-coated tablet contains 300 mg aliskiren (as hemifumarate). 

 

 

3. LIST OF EXCIPIENTS 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

280 film-coated tablets 

Multipack comprising 20 packs, each containing 14 tablets. 

98 film-coated tablets 

Multipack comprising 2 packs, each containing 49 tablets. 

 

 

5. METHOD AND ROUTE(S) OF ADMINISTRATION 

 

Oral use. 

Read the package leaflet before use. 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE REACH AND SIGHT OF CHILDREN 

 

Keep out of the reach and sight of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 

 

8. EXPIRY DATE 

 

EXP 

 

 

9. SPECIAL STORAGE CONDITIONS 

 

Do not store above 30°C. 

Store in the original package in order to protect from moisture. 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



55 

 

 

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

West Sussex, RH12 5AB 

United Kingdom 

 

 

12. MARKETING AUTHORISATION NUMBER(S) 

 

EU/1/07/407/039 98 film-coated tablets (2x49) (perforated unit-dose blister) 

EU/1/07/407/040 280 film-coated tablets (20x14) 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

Medicinal product subject to medical prescription. 

 

 

15. INSTRUCTIONS ON USE 

 

 

16. INFORMATION IN BRAILLE 

 

Sprimeo 300 mg 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



56 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

B. PACKAGE LEAFLET 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



57 

PACKAGE LEAFLET: INFORMATION FOR THE USER 

 

Sprimeo 150 mg film-coated tablets 

Aliskiren 

 

 

Read all of this leaflet carefully before you start taking this medicine. 

- Keep this leaflet. You may need to read it again. 

- If you have any further questions, ask your doctor or pharmacist. 

- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even 

if their symptoms are the same as yours. 

- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, 

please tell your doctor or pharmacist. 

 

 

In this leaflet: 

1. What Sprimeo is and what it is used for 

2. Before you take Sprimeo 

3. How to take Sprimeo 

4. Possible side effects 

5. How to store Sprimeo 

6. Further information 

 

 

 

1. WHAT SPRIMEO IS AND WHAT IT IS USED FOR 

 

Sprimeo belongs to a new class of medicines called renin inhibitors. Sprimeo helps to lower high 

blood pressure. Renin inhibitors reduce the amount of angiotensin II the body can produce. 

Angiotensin II causes blood vessels to tighten, which increases the blood pressure. Reducing the 

amount of angiotensin II allows the blood vessels to relax, which lowers blood pressure. 

 

High blood pressure increases the workload of the heart and arteries. If this continues for a long time, 

it can damage the blood vessels of the brain, heart and kidneys, and may result in a stroke, heart 

failure, heart attack or kidney failure. Lowering the blood pressure to a normal level reduces the risk 

of developing these disorders. 

 

 

2. BEFORE YOU TAKE SPRIMEO 

 

Do not take Sprimeo 

- if you are allergic (hypersensitive) to aliskiren or any of the other ingredients of Sprimeo. If you 

think you may be allergic, ask your doctor for advice. 

- if you have experienced the following forms of angioedema (difficulties in breathing or 

swallowing, or swelling of the face, hands and feet, eyes, lips and/or tongue): 

- angioedema when taking aliskiren. 

- hereditary angioedema. 

- angioedema without any known cause. 

- during the last 6 months of pregnancy or if you are breast-feeding, see section Pregnancy and 

breastfeeding. 

- if you are taking ciclosporin (a medicine used in transplantation to prevent organ rejection or 

for other conditions, e.g. rheumathoid arthritis or atopic dermatitis), itraconazole (a medicine 

used to treat fungal infections) or quinidine (a medicine used to correct heart rhythm). 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



58 

- if you have diabetes mellitus or impaired kidney function and you are treated with either of the 

following classes of medicines used to treat high blood pressure: 

- an “angiotensin converting enzyme inhibitor” such as enalapril, lisinopril, ramipril etc. 

or 

- an “angiotensin 2 receptor blocker” such as valsartan, telmisartan, irbesartan etc. 

 

Take special care with Sprimeo 

- if you are taking a diuretic (a type of medicine also known as “water” tablets which increases 

the amount of urine you produce). 

- if you are taking either of the following classes of medicines used to treat high blood pressure: 

- an “angiotensin converting enzyme inhibitor” such as enalapril, lisinopril, ramipril etc. 

or 

- an “angiotensin 2 receptor blocker” such as valsartan, telmisartan, irbesartan etc. 

- if you have impaired kidney function, your doctor will carefully consider whether Sprimeo is 

suitable for you and may wish to monitor you carefully. 

- if you experience angioedema (difficulties in breathing, or swallowing, or swelling of the face, 

hands and feet, eyes, lips and/or tongue). If this happens, stop taking Sprimeo and contact your 

doctor. 

 

If any of these apply to you, tell your doctor before you take Sprimeo. 

 

The use of Sprimeo in children and adolescents is not recommended. 

The usual dose of Sprimeo for patients aged 65 years or older is 150 mg. 

 

Using other medicines 

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, 

including medicines obtained without a prescription. 

 

Your doctor may need to change your dose and/or to take other precautions if you are taking one of 

the following medicines: 

- medicines that increase the amount of potassium in your blood. These include potassium-

sparing diuretics, potassium supplements. 

- furosemide, a medicine belonging to the type known as diuretics, or “water” tablets, which is 

used to increase the amount of urine you produce. 

- one of the following classes of medicines used to treat high blood pressure: 

- an “angiotensin converting enzyme inhibitor” such as enalapril, lisinopril, ramipril etc. 

or 

- an “angiotensin 2 receptor blocker” such as valsartan, telmisartan, irbesartan etc. 

- ketoconazole, a medicine used to treat fungal infections. 

- verapamil, a medicine used to lower high blood pressure, to correct heart rhythm or to treat 

angina pectoris. 

- certain types of pain killers called non-steroidal anti-inflammatory medicines (NSAIDs). 

 

Taking Sprimeo with food and drink 

You should take Sprimeo with a light meal once a day, preferably at the same time each day. You 

should not take Sprimeo together with grapefruit juice. 

 

Pregnancy and breast-feeding 

Do not take Sprimeo if you are pregnant. It is important to talk to your doctor immediately if you 

think you may be pregnant or are planning to become pregnant. Do not breast-feed if you are taking 

Sprimeo. 

 

Ask your doctor or pharmacist for advice before taking any medicine. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



59 

Driving and using machines 

You may feel dizzy and this can affect your ability to concentrate. Before you drive a vehicle, use 

machinery, or carry out other activities that require concentration, you should make sure you know 

how you react to the effects of Sprimeo. 

 

 

3. HOW TO TAKE SPRIMEO 

 

Always take Sprimeo exactly as your doctor has told you. You should check with your doctor or 

pharmacist if you are not sure. 

 

People who have high blood pressure often do not notice any signs of the problem. Many may feel 

quite normal. It is very important that you take this medicine exactly as your doctor tells you to get the 

best results and reduce the risk of side effects. Keep your appointments with the doctor even if you 

are feeling well. 

 

The usual starting dose is one 150 mg tablet once daily. 

 

Depending on how you respond to the treatment your doctor may prescribe a higher dose of one 

300 mg tablet once daily. Your doctor may prescribe Sprimeo together with other medicines used to 

treat high blood pressure. 

 

Method of administration 

It is recommended that you take the tablets with some water. You should take Sprimeo with a light 

meal once a day, preferably at the same time each day. You should not take Sprimeo together with 

grapefruit juice. 

 

If you take more Sprimeo than you should 

If you have accidentally taken too many Sprimeo tablets, consult a doctor immediately. You may 

require medical attention. 

 

If you forget to take Sprimeo 

If you forget to take a dose of Sprimeo, take it as soon as you remember and then take the next dose at 

its usual time. However, if it is almost time for your next dose you should simply take the next tablet 

at the usual time. Do not take a double dose to make up for a forgotten dose. 

 

 

4. POSSIBLE SIDE EFFECTS 

 

Like all medicines, Sprimeo can cause side effects, although not everybody gets them. 

 

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please 

tell your doctor or pharmacist. You may need to stop Sprimeo. 

 

Common (affecting less than 1 in 10 patients): Diarrhoea, joint pain (arthralgia), high level of 

potassium in the blood, dizziness. 

Uncommon (affecting less than 1 in 100 patients): Skin rash (this may also be a sign of allergic 

reactions or angioedema – see “Rare” side effects below), kidney problems including acute renal 

failure (severely decreased urine output), swelling of hands, ankles or feet (peripheral oedema), severe 

skin reactions (toxic epidermal necrolysis and/or oral mucosal reactions - red skin, blistering of the 

lips, eyes or mouth, skin peeling, fever), low blood pressure. 

Rare (affecting less than 1 in 1,000 patients): Allergic reactions (hypersensitivity) and angioedema 

(the symptoms of which can include difficulties in breathing or swallowing, rash, itching, hives or 

swelling of the face, hands and feet, eyes, lips and/or tongue, dizziness), increased level of creatinine 

in the blood. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



60 

 

5. HOW TO STORE SPRIMEO 

 

Keep out of the reach and sight of children. 

Do not use Sprimeo after the expiry date which is stated on the carton and blister. The expiry date 

refers to the last day of that month. 

Do not store above 30°C. 

Store in the original package in order to protect from moisture. 

 

 

6. FURTHER INFORMATION 

 

What Sprimeo contains 

- The active substance is aliskiren (as hemifumarate) 150 mg. 

- The other ingredients are crospovidone, hypromellose, magnesium stearate, macrogol, 

microcrystalline cellulose, povidone, colloidal anhydrous silica, talc, titanium dioxide (E 171), 

black iron oxide (E 172), red iron oxide (E 172). 

 

What Sprimeo looks like and contents of the pack 

Sprimeo 150 mg film coated tablets are light-pink, biconvex round tablets, imprinted “IL” on one side 

and “NVR” on the other side. 

 

Sprimeo is available in packs containing 7, 14, 28, 30, 50, 56, 84, 90, 98 or 280 tablets. Packs 

containing 84 (3x28), 98 (2x49) or 280 (20x14) tablets are multi-packs. Not all pack sizes may be 

available in your country. 

 

 

Marketing Authorisation Holder 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

West Sussex, RH12 5AB 

United Kingdom 

 

Manufacturer 

Novartis Farma S.p.A. 

Via Provinciale Schito 131 

I-80058 Torre Annunziata/NA 

Italy 

 

For any information about this medicine, please contact the local representative of the Marketing 

Authorisation Holder: 

 

België/Belgique/Belgien 

Novartis Pharma N.V. 

Tél/Tel: +32 2 246 16 11 

 

Luxembourg/Luxemburg 

Novartis Pharma GmbH 

Tél/Tel: +49 911 273 0 

 

България 

Novartis Pharma Services Inc. 

Тел.: +359 2 489 98 28 

 

Magyarország 

Novartis Hungária Kft. Pharma 

Tel.: +36 1 457 65 00 

Česká republika 

Novartis s.r.o. 

Tel: +420 225 775 111 

 

Malta 

Novartis Pharma Services Inc. 

Tel: +356 2298 3217 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



61 

 

Danmark 

Novartis Healthcare A/S 

Tlf: +45 39 16 84 00 

 

Nederland 

Novartis Pharma B.V. 

Tel: +31 26 37 82 111 

Deutschland 

Novartis Pharma GmbH 

Tel: +49 911 273 0 

 

Norge 

Novartis Norge AS 

Tlf: +47 23 05 20 00 

Eesti 

Novartis Pharma Services Inc. 

Tel: +372 66 30 810 

 

Österreich 

Novartis Pharma GmbH 

Tel: +43 1 86 6570 

Ελλάδα 

Novartis (Hellas) A.E.B.E. 

Τηλ: +30 210 281 17 12 

 

Polska 

Novartis Poland Sp. z o.o. 

Tel.: +48 22 375 4888 

España 

Novartis Farmacéutica, S.A. 

Tel: +34 93 306 42 00 

 

Portugal 

Novartis Farma - Produtos Farmacêuticos, S.A. 

Tel: +351 21 000 8600 

France 

Novartis Pharma S.A.S. 

Tél: +33 1 55 47 66 00 

 

România 

Novartis Pharma Services Romania SRL 

Tel: +40 21 31299 01 

Ireland 

Novartis Ireland Limited 

Tel: +353 1 260 12 55 

 

Slovenija 

Novartis Pharma Services Inc. 

Tel: +386 1 300 75 50 

Ísland 

Vistor hf. 

Sími: +354 535 7000 

 

Slovenská republika 

Novartis Slovakia s.r.o. 

Tel: +421 2 5542 5439 

 

Italia 

Novartis Farma S.p.A. 

Tel: +39 02 96 54 1 

Suomi/Finland 

Novartis Finland Oy 

Puh/Tel: +358 (0)10 6133 200 

 

Κύπρος 

Novartis Pharma Services Inc. 

Τηλ: +357 22 690 690 

 

Sverige 

Novartis Sverige AB 

Tel: +46 8 732 32 00 

 

Latvija 

Novartis Pharma Services Inc. 

Tel: +371 67 887 070 

 

United Kingdom 

Novartis Pharmaceuticals UK Ltd. 

Tel: +44 1276 698370 

 

Lietuva 

Novartis Pharma Services Inc. 

Tel: +370 5 269 16 50 

 

 

 

This leaflet was last approved in 

 

Detailed information on this medicine is available on the European Medicines Agency website: 

http://www.ema.europa.eu 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



62 

PACKAGE LEAFLET: INFORMATION FOR THE USER 

 

Sprimeo 300 mg film-coated tablets 

Aliskiren 

 

 

Read all of this leaflet carefully before you start taking this medicine. 

- Keep this leaflet. You may need to read it again. 

- If you have any further questions, ask your doctor or pharmacist. 

- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even 

if their symptoms are the same as yours. 

- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, 

please tell your doctor or pharmacist. 

 

 

In this leaflet: 

1. What Sprimeo is and what it is used for 

2. Before you take Sprimeo 

3. How to take Sprimeo 

4. Possible side effects 

5. How to store Sprimeo 

6. Further information 

 

 

 

1. WHAT SPRIMEO IS AND WHAT IT IS USED FOR 

 

Sprimeo belongs to a new class of medicines called renin inhibitors. Sprimeo helps to lower high 

blood pressure. Renin inhibitors reduce the amount of angiotensin II the body can produce. 

Angiotensin II causes blood vessels to tighten, which increases the blood pressure. Reducing the 

amount of angiotensin II allows the blood vessels to relax, which lowers blood pressure. 

 

High blood pressure increases the workload of the heart and arteries. If this continues for a long time, 

it can damage the blood vessels of the brain, heart and kidneys, and may result in a stroke, heart 

failure, heart attack or kidney failure. Lowering the blood pressure to a normal level reduces the risk 

of developing these disorders. 

 

 

2. BEFORE YOU TAKE SPRIMEO 

 

Do not take Sprimeo 

- if you are allergic (hypersensitive) to aliskiren or any of the other ingredients of Sprimeo. If you 

think you may be allergic, ask your doctor for advice. 

- if you have experienced the following forms of angioedema (difficulties in breathing or 

swallowing, or swelling of the face, hands and feet, eyes, lips and/or tongue): 

- angioedema when taking aliskiren. 

- hereditary angioedema. 

- angioedema without any known cause. 

- during the last 6 months of pregnancy or if you are breast-feeding, see section Pregnancy and 

breastfeeding. 

- if you are taking ciclosporin (a medicine used in transplantation to prevent organ rejection or 

for other conditions, e.g. rheumathoid arthritis or atopic dermatitis), itraconazole (a medicine 

used to treat fungal infections) or quinidine (a medicine used to correct heart rhythm). 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



63 

- if you have diabetes mellitus or impaired kidney function and you are treated with either of the 

following classes of medicines used to treat high blood pressure: 

- an “angiotensin converting enzyme inhibitor” such as enalapril, lisinopril, ramipril etc. 

or 

- an “angiotensin 2 receptor blocker” such as valsartan, telmisartan, irbesartan etc. 

 

Take special care with Sprimeo 

- if you are taking a diuretic (a type of medicine also known as “water” tablets which increases 

the amount of urine you produce). 

- if you are taking either of the following classes of medicines used to treat high blood pressure: 

- an “angiotensin converting enzyme inhibitor” such as enalapril, lisinopril, ramipril etc. 

or 

- an “angiotensin 2 receptor blocker” such as valsartan, telmisartan, irbesartan etc. 

- if you have impaired kidney function, your doctor will carefully consider whether Sprimeo is 

suitable for you and may wish to monitor you carefully. 

- if you experience angioedema (difficulties in breathing, or swallowing, or swelling of the face, 

hands and feet, eyes, lips and/or tongue). If this happens, stop taking Sprimeo and contact your 

doctor. 

 

If any of these apply to you, tell your doctor before you take Sprimeo. 

 

The use of Sprimeo in children and adolescents is not recommended. 

The usual dose of Sprimeo for patients aged 65 years or older is 150 mg. 

 

Using other medicines 

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, 

including medicines obtained without a prescription. 

 

Your doctor may need to change your dose and/or to take other precautions if you are taking one of 

the following medicines: 

- medicines that increase the amount of potassium in your blood. These include potassium-

sparing diuretics, potassium supplements. 

- furosemide, a medicine belonging to the type known as diuretics, or “water” tablets, which is 

used to increase the amount of urine you produce. 

- one of the following classes of medicines used to treat high blood pressure: 

- an “angiotensin converting enzyme inhibitor” such as enalapril, lisinopril, ramipril etc. 

or 

- an “angiotensin 2 receptor blocker” such as valsartan, telmisartan, irbesartan etc. 

- ketoconazole, a medicine used to treat fungal infections. 

- verapamil, a medicine used to lower high blood pressure, to correct heart rhythm or to treat 

angina pectoris. 

- certain types of pain killers called non-steroidal anti-inflammatory medicines (NSAIDs). 

 

Taking Sprimeo with food and drink 

You should take Sprimeo with a light meal once a day, preferably at the same time each day. You 

should not take Sprimeo together with grapefruit juice. 

 

Pregnancy and breast-feeding 

Do not take Sprimeo if you are pregnant. It is important to talk to your doctor immediately if you 

think you may be pregnant or are planning to become pregnant. Do not breast-feed if you are taking 

Sprimeo. 

 

Ask your doctor or pharmacist for advice before taking any medicine. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



64 

Driving and using machines 

You may feel dizzy and this can affect your ability to concentrate. Before you drive a vehicle, use 

machinery, or carry out other activities that require concentration, you should make sure you know 

how you react to the effects of Sprimeo. 

 

 

3. HOW TO TAKE SPRIMEO 

 

Always take Sprimeo exactly as your doctor has told you. You should check with your doctor or 

pharmacist if you are not sure. 

 

People who have high blood pressure often do not notice any signs of the problem. Many may feel 

quite normal. It is very important that you take this medicine exactly as your doctor tells you to get the 

best results and reduce the risk of side effects. Keep your appointments with the doctor even if you 

are feeling well. 

 

The usual starting dose is one 150 mg tablet once daily. 

 

Depending on how you respond to the treatment your doctor may prescribe a higher dose of one 

300 mg tablet once daily. Your doctor may prescribe Sprimeo together with other medicines used to 

treat high blood pressure. 

 

Method of administration 

It is recommended that you take the tablets with some water. You should take Sprimeo with a light 

meal once a day, preferably at the same time each day. You should not take Sprimeo together with 

grapefruit juice. 

 

If you take more Sprimeo than you should 

If you have accidentally taken too many Sprimeo tablets, consult a doctor immediately. You may 

require medical attention. 

 

If you forget to take Sprimeo 

If you forget to take a dose of Sprimeo, take it as soon as you remember and then take the next dose at 

its usual time. However, if it is almost time for your next dose you should simply take the next tablet 

at the usual time. Do not take a double dose to make up for a forgotten dose. 

 

 

4. POSSIBLE SIDE EFFECTS 

 

Like all medicines, Sprimeo can cause side effects, although not everybody gets them. 

 

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please 

tell your doctor or pharmacist. You may need to stop Sprimeo. 

 

Common (affecting less than 1 in 10 patients): Diarrhoea, joint pain (arthralgia), high level of 

potassium in the blood, dizziness. 

Uncommon (affecting less than 1 in 100 patients): Skin rash (this may also be a sign of allergic 

reactions or angioedema – see “Rare” side effects below), kidney problems including acute renal 

failure (severely decreased urine output), swelling of hands, ankles or feet (peripheral oedema), severe 

skin reactions (toxic epidermal necrolysis and/or oral mucosal reactions - red skin, blistering of the 

lips, eyes or mouth, skin peeling, fever) , low blood pressure. 

Rare (affecting less than 1 in 1,000 patients): Allergic reactions (hypersensitivity) and angioedema 

(the symptoms of which can include difficulties in breathing or swallowing, rash, itching, hives or 

swelling of the face, hands and feet, eyes, lips and/or tongue, dizziness), increased level of creatinine 

in the blood. 

 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



65 

 

5. HOW TO STORE SPRIMEO 

 

Keep out of the reach and sight of children. 

Do not use Sprimeo after the expiry date which is stated on the carton and blister. The expiry date 

refers to the last day of that month. 

Do not store above 30°C. 

Store in the original package in order to protect from moisture. 

 

 

6. FURTHER INFORMATION 

 

What Sprimeo contains 

- The active substance is aliskiren (as hemifumarate) 300 mg. 

- The other ingredients are crospovidone, hypromellose, magnesium stearate, macrogol, 

microcrystalline cellulose, povidone, colloidal anhydrous silica, talc, titanium dioxide (E 171), 

black iron oxide (E 172), red iron oxide (E 172). 

 

What Sprimeo looks like and contents of the pack 

Sprimeo 300 mg film coated tablets are light-red, biconvex, ovaloid tablets, imprinted “IU” on one 

side and “NVR” on the other side. 

 

Sprimeo is available in packs containing 7, 14, 28, 30, 50, 56, 84, 90, 98 or 280 tablets. Packs 

containing 84 (3x28), 90 (3x30), 98 (2x49) or 280 (20x14) tablets are multi-packs. Not all pack sizes 

may be available in your country. 

 

 

Marketing Authorisation Holder 

Novartis Europharm Limited 

Wimblehurst Road 

Horsham 

West Sussex, RH12 5AB 

United Kingdom 

 

Manufacturer 

Novartis Farma S.p.A. 

Via Provinciale Schito 131 

I-80058 Torre Annunziata/NA 

Italy 

 

For any information about this medicine, please contact the local representative of the Marketing 

Authorisation Holder: 

 

België/Belgique/Belgien 

Novartis Pharma N.V. 

Tél/Tel: +32 2 246 16 11 

 

Luxembourg/Luxemburg 

Novartis Pharma GmbH 

Tél/Tel: +49 911 273 0 

 

България 

Novartis Pharma Services Inc. 

Тел.: +359 2 489 98 28 

 

Magyarország 

Novartis Hungária Kft. Pharma 

Tel.: +36 1 457 65 00 

Česká republika 

Novartis s.r.o. 

Tel: +420 225 775 111 

 

Malta 

Novartis Pharma Services Inc. 

Tel: +356 2298 3217 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d



66 

 

Danmark 

Novartis Healthcare A/S 

Tlf: +45 39 16 84 00 

 

Nederland 

Novartis Pharma B.V. 

Tel: +31 26 37 82 111 

Deutschland 

Novartis Pharma GmbH 

Tel: +49 911 273 0 

 

Norge 

Novartis Norge AS 

Tlf: +47 23 05 20 00 

Eesti 

Novartis Pharma Services Inc. 

Tel: +372 66 30 810 

 

Österreich 

Novartis Pharma GmbH 

Tel: +43 1 86 6570 

Ελλάδα 

Novartis (Hellas) A.E.B.E. 

Τηλ: +30 210 281 17 12 

 

Polska 

Novartis Poland Sp. z o.o. 

Tel.: +48 22 375 4888 

España 

Novartis Farmacéutica, S.A. 

Tel: +34 93 306 42 00 

 

Portugal 

Novartis Farma - Produtos Farmacêuticos, S.A. 

Tel: +351 21 000 8600 

France 

Novartis Pharma S.A.S. 

Tél: +33 1 55 47 66 00 

 

România 

Novartis Pharma Services Romania SRL 

Tel: +40 21 31299 01 

Ireland 

Novartis Ireland Limited 

Tel: +353 1 260 12 55 

 

Slovenija 

Novartis Pharma Services Inc. 

Tel: +386 1 300 75 50 

Ísland 

Vistor hf. 

Sími: +354 535 7000 

 

Slovenská republika 

Novartis Slovakia s.r.o. 

Tel: +421 2 5542 5439 

 

Italia 

Novartis Farma S.p.A. 

Tel: +39 02 96 54 1 

Suomi/Finland 

Novartis Finland Oy 

Puh/Tel: +358 (0)10 6133 200 

 

Κύπρος 

Novartis Pharma Services Inc. 

Τηλ: +357 22 690 690 

 

Sverige 

Novartis Sverige AB 

Tel: +46 8 732 32 00 

 

Latvija 

Novartis Pharma Services Inc. 

Tel: +371 67 887 070 

 

United Kingdom 

Novartis Pharmaceuticals UK Ltd. 

Tel: +44 1276 698370 

 

Lietuva 

Novartis Pharma Services Inc. 

Tel: +370 5 269 16 50 

 

 

 

This leaflet was last approved in 

 

Detailed information on this medicine is available on the European Medicines Agency website: 

http://www.ema.europa.eu 

Me
dic

ina
l p

rod
uc

t n
o l

on
ge

r a
uth

ori
se

d


	SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
	B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
	C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
	A. LABELLING
	B. PACKAGE LEAFLET